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11.0 Summary 
Resistance of the malaria parasite to treatment is increasing globally. One method of 
delaying this may be through the use of combination therapy with an artemisinin 
derivative and a standard antimalarial drug. In this randomised crossover study the anti-
malarials amodiaquine (AQ) and artesunate (AS) were given to 15 normal healthy 
volunteers, both as individual agents and together, over three study phases. 
Serial plasma samples were taken for determination of pharmacokinetic (PK) 
parameters of the drugs: maximum plasma concentration (Cmax), time to achieve Cmax 
(Tmax) and the area under the concentration time curve (AUC). These were determined 
for the drug combination and compared to the drugs given individually. The parameters 
of the major, active metabolites of the parent drugs, dihydroartemisinin (DHAS) and 
desethylamodiaquine were calculated as well. The tolerability of the combination was 
assessed in the volunteers over the study period. 
Thirteen subjects completed the study. Two subjects were withdrawn; one after 
generalised flushing was experienced shortly after amodiaquine dosing and the other 
due to concomitant administration of f1uoxetine. 
There were no significant changes in the PK parameters of AS when given alone or in 
combination with AQ. For DHAS, there was a significant decrease in the Cmax (446.2 vs 
844.5 ng/ml, p=0.01), a significant prolongation of the half-life of DHAS (2.12h vs 1.67h, 
p=0.01), and a significant decrease in the AUC to 24 hours (1229 vs 1743 ng.h/ml, 
p=0.03) with the AS-AQ combination compared to AS alone. The AUC to infinity was not 
significantly different. 
Compared to AQ given alone, there was a significant decrease in the AQ Cmax (22.9 
ng/ml vs 30.01 ng/ml, p=0.03) and AUCo-24 (114.6 vs 171.1 ng.h/ml, p=0.04) in the AQ-
AS combination. Comparing AQ-AS with AQ alone, D-amodiaquine reached its Tmax 
earlier (2.25 vs 3.63h, p=0.007) and had a shortened half-life (135.6 vs 242.0h, p=0.03). 
The AUC values at 24 hours and infinity did not change significantly. 
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12.0 Introduction 
Resistance of Plasmodium falciparum to almost all antimalarial drugs has become 
widespread in Southeast Asia, Africa and South America (Wernsdorfer and Payne, 
1991). The only exception to this situation is with the artemisinin derivatives which have 
recently been introduced for widespread use in Southeast Asia (Price, 2000). Cross-
resistance between compounds of the same class magnifies the problem. 
Antifolate resistance in both P.falciparum and P. vivax developed rapidly following the 
introduction of pyrimethamine in many parts of the tropics (WHO, 1984). The fixed 
combination of sulfadoxine/pyrimethamine has been very successful, but is no longer 
effective in many areas of Southeast Asia (White, 1992) and its efficacy is declining in 
East and West Africa (Garcia-Vidal et ai, 1989). Mefloquine resistance was reported 
even before the drug had been routinely used because of cross resistance with quinine 
(Brasseur et ai, 1990). Resistance to mefloquine has now severely curtailed its efficacy 
in several parts of Southeast Asia (Nosten et ai, 1991; Fontanet et ai, 1993). 
Halofantrine resistance has emerged concomitantly (Basco et ai, 1991; Brasseur et ai, 
1992). When atovaquone was used alone in preliminary clinical trials, 28% of patients 
had recrudescent infections associated with the development of resistance 
(Looareesuwan et ai, 1996). Quinine and chloroquine have enjoyed longer periods of 
effective use, but in almost all malaria endemic areas, chloroquine is no longer effective 
treatment for falciparum malaria (Wernsdorfer, 1991) and P. vivax has developed 
resistance in some parts of Oceania (Murphy et ai, 1993). Quinine effectiveness or 
resistance too, is threatened in some parts of the world (Pukrittayakamee et ai, 1994). 
In the absence of new and effective methods of vector control and the limited prospects 
for a rapid development of safe and effective malaria vaccines (Playfair et ai, 1990; 
Nosten et ai, 1996), drugs retain a key role in the control of malaria, particularly in 
preventing death and reducing morbidity. This situation has stimulated research into 
better and more effective usage of the currently available drugs, the development of new 
novel antimalarial agents and the introduction of drug combinations. Recently White and 
Olliara (1996) reviewed the rationale for combination chemotherapy for malaria. 
Essentially, while waiting for new drugs to be discovered and hopefully deployed, 
, , . 
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I 3.0 Background 
Resistance is the prime determinant of drug's lifespan, and protection of drugs against 
the development of resistance is a key factor in the fight against malaria. The WHO TOR 
has initiated research into drug resistance and policies, which will primarily generate 
accurate data to inform policy makers and reform current policies based on research 
results. 
Drug policies play an important role in the emergence and spread of resistance. Thus 
far, drugs have been used alone (Single agent chemotherapy) and exploited to the point 
where they become ineffective; then a new drug introduced. Such an attitude assumes 
unlimited resources and indefinite availability of new drugs. However the pharmaceutical 
industry does not consider the malaria market profitable, and new drugs are not readily 
available. 
Amongst the various activities that are or will be conducted under this new initiative is 
research to optimize drug treatments, which includes an array of studies on drug 
combinations aimed at gaining "extra-mileage" from existing antimalarial drugs. The 
scientific rationale of this approach is to use a rapidly acting, short half life drug to 
reduce substantially the parasite biomass; this is readily achieved by an artemisinin 
derivative. The remaining parasites are then killed by high concentrations of the 
companion drug (White, 1997). Several artesunate based combinations have been 
studied in clinical trials, including one using artesunate with amodiaquine. von Seidlein et 
ai, ~OOO; Dorsey et ai, 2002; Marquino et ai, 2003) 
In three trials of AQ-AS versus AQ alone, 941 children (400 in Kenya, 321 in Senegal, 
and 220 in Gabon) who were .:::.10 years with uncomplicated Plasmodium fa/ciparum 
malaria were randomly assigned amodiaquine (10 mglkglday for 3 days) plus artesunate 
(4 mglkg per day for 3 days) or amodiaquine (as above) and placebo (for 3 days). The 
primary endpoints were parasitological cure rates at days 14 and 28. The data were 
analysed by intention to treat. The day-14 cure rates for amodiaquine-artesunate versus 
amodiaquine were: 175/192 (91%) versus 140/188 (74%) in Kenya (p<0.0001). 148/160 
(93%) versus 147/157 (94%) in Senegal (p=0.7), and 92/94 (98%) versus 86/96 (90%) in 
Gabon (p=0.02). The corresponding rates for day 28 were: 123/180 (68%) versus 
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14.0 Rationale 
These studies are based on the concept primarily developed by White (1997,1998) and 
others (Peters, 1990) of initial parasite biomass reduction to protect vulnerable 
antimalarials. Antimalarials with long terminal elimination phases and therefore long 
residence have a particular propensity to generate resistance. 
There is good theoretical basis for the chances of a drug-reSistant mutant appearing to 
be reduced if such drugs are combined with another effective antimalarial with a different 
mechanism of action. This benefit is expected to be greater when an antimalarial is 
combined with an artemisinin derivative. Through its rapid onset of action the latter will 
leave a small residual parasite biomass for the companion drug to eradicate at a time of 
maximum blood concentrations; similarly, the parasites will never be exposed to the 
artemisinin derivative alone (given its short half-life). Artemisinin derivatives are also 
effective in reducing transmissibility and thus the likelihood of resistant mutants being 
transmitted. 
I 5.0 Objectives 
The objectives of this study were: 
1. To investigate the tolerability of concomitant oral administration of artesunate and 
amodiaquine in healthy normal volunteers (HNV). 
2. To investigate the pharmacokinetic properties of the same combination. The kinetics 
of both the parent drugs and the primary active metabolites (dihydro-artesunate and 
desethylamodiaquine) were determined. 
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16.0 Study design 
6.1 Description 
The trial design was a single randomised three-phase crossover model in a total of 15 
healthy normal subjects. All the subjects took artesunate, the short half-life drug in the 
first phase, in order to complete the pharmacokinetics of this drug prior to the 
administration of amodiaquine, with its long half-life. 
All trial drugs were given as a stat dose with 200ml tap water on an empty stomach after 
an overnight fast. For a week before the study, during the study and during the washout 
periods the volunteers took no other drugs or alcohol. 
Phase one: All subjects were initially administered with oral artesunate (4 
mg/kg). 
Phases two and three: One week later subjects were randomly allocated 
to one of the treatment groups: 
(i) A single oral dose of sodium artesunate (4 mg/kg) and 
amodiaquine base (10 mg/kg). 
OR 
(ii) A single oral dose of amodiaquine {10 mg/kg} alone. 
At the end of a 21 day washout period, the subjects were crossed over. 
The elimination half-life of artesunate is O.53hr and that of amodiaquine 5.2 hours. The 
washout period for this study was based on the elimination half-life of 
desethylamodiaquine, the active metabolite of amodiaquine, which is between 9 and 18 
days {Dollery, C. 1991, Krishna, S et al. 1996, Pussard, E et al 1994}. 
6.2 Study drug: 
The medicines were procured by representatives at the World Health organisation and 
made available for the study. The artesunate was produced by Sanofi Winthrop as 
Arsumax@ 50mg tablets. The amodiaquine was produced by Parke Davis as CamoquidF) 
200mg tablets. 
Dr Catherine Orrell <catherine.orrell@hiv-research.org.za> 
14 1 
nOll"l'n,"rn"'r! in 
were same n<:>n:::3lrTmlil'> 
"' ... ,,,."'''''''' were were 
Artesunate amodiaquine pharmacokinetic report. Page 15 of 137 
17.0 STUDY POPULATION: 
Fifteen healthy normal volunteers of either sex who met all the inclusion criteria and 
none of the exclusion criteria were recruited in the 30 days prior to study 
commencement. 
Informed consent was obtained from each subject admitted to the study. All subjects 
were fluent in English. The consent form is attached as Appendix A. 
7.1 Inclusion Criteria 
• Age 18-45 years 
• Written consent was given after reading the patient information leaflet. PartiCipation 
was voluntary and volunteers were fully informed of possible side effects. They were 
advised that they were free to withdraw at any time. 
• No significant abnormal findings on history or examination, particularly no prior liver 
disease, cardiovascular disease (including arrhythmias) or peripheral neuropathy. 
• No clinically significant abnormalities on haematology, liver and renal function tests. 
• Negative pregnancy test (women). 
• Normal electrocardiogram. 
• No history of antimalarial ingestion in the preceding two months. 
• No other drugs or medications, including over-the counter preparations, ingested in 
the preceding week. 
• Adequate venous access. 
7.2 Exclusion Criteria 
o Refusal of consent. 
o Biological or electrocardiograph anomalies. 
o Presence of hepatic, renal and gastrOintestinal disorders. 
o Smokers (>5/day), abuse of alcohol or recreational drugs 
o Presence of malaria paraSites on a thick smear 
o Subjects having been in a malarial area in the preceding 8 weeks 
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Is.o STUDY PROCEDURES AND SCHEDULES 
8.1 Pre-study visit: (visit 1) 
In the 30 days prior to the study the volunteers underwent a screening process (Visit 1) 
to ensure selection of suitable candidates for the study. Fifteen healthy volunteers 
who fulfilled all the inclusion and none of the exclusion criteria were recruited. 
Visit 1 involved a medical history and clinical examination including age, sex, race, 
evidence of physical illness or current disease, weight, height, blood pressure, heart 
rate and temperature. Blood was taken for chemistry (AST, AL T, total bilirubin, 
sodium, potassium, creatinine and glucose), haematology (full blood count and 
differential) and for a malaria smear. Women were screened for pregnancy by 
quantitative assay of beta-HCG. Urine was screened for drugs of abuse by semi-
quantitative assays including cannabinoids, cocaine, amphetamines, barbiturates, 
opiates and benzodiazepines. An ECG was performed to exclude conduction 
abnormalities. 
8.2 Peri-study restrictions: 
Volunteers were asked to avoid alcohol, caffeine, any medications (without consulting 
the investigator) and strenuous exercise over the study period. They we're required 
to fast from midnight prior to each study day. 
8.2 On-Treatment and Post-Treatment 
8.2.1. Study days (visits 2, 4 and 14) 
Subjects were admitted to the ward at 7am on each study day after an overnight fast. 
Their vital signs (heart rate, temperature and blood pressure) were recorded. 
All study day venous blood samples (2 or 3 X 5ml each) were drawn by a vacutainer 
system directly into heparinized tubes for further processing. Specimens in the first 
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I 9.0 Methods of evaluation: 
9.1 Blood tests for screening and adverse event detection 
Haematology, chemical pathology and urine drug assays were carried out by validated 
laboratories of the University of Cape Town (UCT), according to standard operating 
procedures. Normal ranges of laboratory variables are presented in Appendix C. 
ECGs were completed by technicians of the Department of Cardiology, UCT, and 
read by the principal investigator. Abnormalities were discussed with cardiology 
consultants. 
Results outside the normal ranges, as assessed to be clinically significant by the 
principal investigator, excluded a volunteer from the study. 
9.2 Drug concentration determination 
The blood sampling times were described previously. Each volunteer would have had 
12 blood samples taken during phase one and 21 samples taken during each of 
phase 2 and 3. The additional samples in the latter phases were taken for the 
. determination of desethylamodiaquine levels. Desethylamodiaquine has an 
elimination half-life between 9 and 18 days (Dollery, C. 1991, Krishna, S et al. 1996, 
Pussard, E et aI1994). The exact times of drug administration and sampling were 
recorded in the case record forms. Samples were collected into dry lithium heparin 
tubes and placed immediately onto melting ice. They were centrifuged within 60 
minutes of collection and transferred to polypropylene tubes for storage in a dark 
environment at -70°C. these samples were kept in storage until at least 12 months 
after study completion. 
Amodiaquine was analysed by HPLC-MS with UV detection while artesunate was 
analysed by HPLC with post-column decomposition followed by UV detection 
(Appendix E). 80th methods are validated. The limit of quantification for the 
artesunate assay was set at 24ng/ml. Levels below this were halved and reported at 
12ng/ml. The 1imit of quantification for the amodiaquine assay was Sng/mf. 
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The effects of treatment on the mean of each haematological parameter (Hb, Hct, 
Platelets, WCC, lymphocytes and neutrophils) were analysed using regression 
analysis, taking repeated measures within patient into account (generalized 
estimating equation). 
9.5 Laboratory analysis: 
Details of the methodology are attached as Appendix E. 
/10.0 Ethical and legal considerations 
This clinical study was conducted in accordance with the principles laid down by the 
World Health Assembly of 1975 on Ethics in Human Experimentation and the 
Helsinki Declaration. The study adhered to the standards established for Good 
Clinical Practices (GCP). The protocol was approved by the University of Cape 
Town's Ethical Committee and the WHO Secretariat committee for research 
Involving Human Subjects (SCRIHS). Each subject was be informed of the nature 
and possible risks of the trials. The Investigator obtained informed written consent 
from every subject participating in the study. The subject was informed that he/she 
was at liberty to abstain from participation in the study and that he/she was free to 
withdraw the consent of participation at anytime. The investigators and study staff 
observed strict confidentiality of the records. After the initial screening procedures a 
coded number recorded the identity of the volunteers. 
Insurance coverage for the participants over the duration of the study was obtained 
from Price Forbes, Jc:>hannesburg. 
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111.0 Results 
11.1 Study subjects: 
Fifteen healthy normal volunteers were selected for the study. This group was largely 
comprised of medical students or staff of the University of Cape Town and their 
families. 
Demographic characteristics: 
The demographics of the study group are detailed in Table 1, together with the dose of 
amodiaquine and artesunate, in milligrams, that each subject received, with the 
milligram per kilogram equivalent. The randomisation table presented in Appendix 8 
presents the sequence in which each subject was dosed. 
Table 1: Demographics and dosing details for each subject (Appendix H). 
Subject race age gender weight height AQ dose AQ mg/kg AS dose AS mg/kg 
(years) (kg) (cm) (mg) (mg) 
A c 20 f 69 169 800 11.59 300 4.35 
B c 42 m 70 166 800 11.43 300 4.29 
C w 23 m 82 185 800 9.76 350 4.27 
D w 22 m 63 173 600 9.52 300 4.76 
E b 23 f 68 158 800 11.76 300 4.41 
F w 34 m 73 180 800 10.96 300 4.11 
G w 23 m 61 171 600 9.84 250 4.10 
H b 22 f 59 159 600 10.17 250 4.24 
J a 19 f 50 161 600 12.00 200 4.00 
K b 24 f 54 157 600 11.11 250 4.63 
L c 22 m 74 181 800 10.81 300 4.05 
M c 21 m 97 189 1000 10.31 400 4.12 
N a 23 m 68 176 800 11.76 300 4.41 
P w 24 m 64 179 600 9.38 250 3.91 
Q b 24 m 58 159 600 10.34 250 4.31 
Means: 24.4 67.33 170.87 10.72 4.26 i 
Std deviation: 5.90 11.61 10.61 0.88 0.23 
a = aSIan, b= black, c = coloured, w = white 
The data for 13 out of the 15 subjects was analysed. Subjects G and H were withdrawn 
after phase two (see Study Completion Status below). The range of weight was 50 to 82 
kilograms (mean 67.3 kg) and the range of height 157 to 189 cm (mean 170.9cm). The 
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11.3 Pharmacokinetic results: 
The data from the 13 patients who completed the study were included in the 
pharmacokinetic analysis. Artesunate and dihydroartesunate (OHAS) results were 
available in August 2001. Amodiaquine results were available by May 2003. Samples 
were stored at -70°C in the interim. Appendices 0-1,0-2 and 0-3 contain the data for 
each study drug and metabolite by individual as well as summary graphs. Raw 
concentration vs. time data by individual for AS, OHAS, AQ and O-amodiaquine, at all 
time points. is available on request from the principal investigator. 
Table 2: Mean pharmacokinetic parameters derived for artesunate and 
dihydroartemisinin with and without amodiaquine. 
I Tmax (SEM) 
Artesunate 0.62 hr 
alone (0.08) 
Artesunate 0.79 hr 
with (1.09) 
amodiaquine 
Paired Hest p=0.25 
(two-tailed p nsd 
value) 
Wicoxon p=0.36 
matched nsd 
pairs 
DHAS alone 0.98 hr 
(0.18) 
DHASwith 1.58 hr 
amodiaquine (0.31) 
Paired Hest p=0.16 
(two-tailed p nsd 
value) 
Wicoxon p=0.12 
matched nsd 
pairs 
nsd = not sigmficantly different 
hr = hour 
Dr Catherine Orrell 
Cmax 
(SEM) 
231.8 ng/ml 
(42.99) 
146.3 ng/ml 
(32.19) 
p=0.12 
nsd 
p=0.09 
nsd 
844.5 ng/ml 
(85.83) 
446.2 ng/ml 
(66.41) 
p=0.007 
sd 
p=0.01 
sd 
Thalf AUC (0-24) AUC (O-inf) 
(SEM) (SEM) (SEM) 
0.44 hr 135.9 168.3 
(0.08) ng.h/ml ng.h/ml 
(24.76) (25.19) 
0.52 hr 122.9 156.6 
(0.07) ng.h/ml ng.h/ml 
(26.40) (26.63) 
p=0.08 p=0.62 p=0.25 
nsd nsd nsd 
p=0.06 p=0.73 p=0.47 
nsd nsd nsd 
1.67 hr 1743 1804 
(0.11) ng.h/ml ng.h/ml 
(133.6) (129.90) 
2.15 hr 1229 1490 
(0.26) ng.h/ml ng.nlml 
(139.50) (137.30) 
p=0.02 p=0.02 p=0.09 
sd sd nsd 
p=0.01 p=0.03 p=0.15 
sd sd nsd 
sd = slgmficant difference 
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Table 2 summarises the mean pharmacokinetic parameters for artesunate (AS) and 
dihydroartesunate). Table 3 summarises the same for amodiaquine (AQ) and 
desethylamodiaquine (D-AQ). 
Table 3: Mean pharmacokinetic parameters derived for amodiaquine and 
desethylamodiaquine with and without artesunate. 
Tmax 
(SEM) 
Amodiaquine 2.38 hr 
(0.33) 
Amodiaquine 1.88 hr 
with (0.29) 
artes u nate 
Paired t-test p=0.33 
(two-tailed p nsd 
value) 
Wicoxon p=0.36 
matched pairs nsd 
0- 3.63 hr 
amodiaquine (0.51 ) 
0- 2.25 hr 
amodiaquine (0.29) 
with 
artes u nate 
Paired Hest p=0.OO7 
(two-tailed p sd 
value) 
Wicoxon p=O.OO7 
matched pairs sd 
.. 
nsd = not slgmflcantly different 
hr = hour 
Cmax 
(SEM) 
30.01 ng/ml 
(3.10) 
22.90 ng/ml 
(2.57) 
p=0.04 
sd 
p=0.03 
sd 
273.40 
ng/ml 
(20.05) 
303.50 
ng/ml 
(45.76) 
p=0.49 
nsd 
p=0.52 
nsd 
Thalf AUC (0-24) AUC (O-inf) 
(SEM) (SEM) (SEM) 
4.90 hr 171.10 221.10 
(1.17) ng.h/ml ng.h/ml 
(29.29) (44.95) 
3.83 hr 114.60 142.30 
(0.31) ng.h/ml ng.h/ml 
(17.56) (18.45) 
p=0.38 p=0.04 P=0.09 
nsd sd Nsd 
p=0.73 p=0.04 P=0.10 
nsd sd nsd 
242.00 hr 12160 15300 
(39.44) ng.h/ml ng.h/ml 
(920.80) (1421.00) 
135.60 hr 10650 12610 
(18.06) ng.h/ml ng.h/ml 
(2066.00) (2978.00) 
p=0.03 p=0.49 P=0.43 
sd nsd nsd 
p=0.03 P=0.23 P=0.15 
sd nsd ,nsd 
sd = slgmficant difference 
The AS half-life of subject F was excluded from this analysis. as this CQuid not be 
accurately calculated as the levels detected were below the levels of quantification for 
this assay. and the prolonged half-life calculated (6.9 hours) was an extreme outlier. As 
the amodiaquine samples for subject N were missing. these could not be included in the 
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above analysis, although this subject's results were included in the artesunate PK 
analysis. 
There was no significant difference in any of the parameters for the parent drug 
artesunate when given with or without amodiaquine. For OHAS, there was a 47.2% 
reduction in Cmax when AS was given in conjunction with amodiaquine. While the Cmax 
was reduced, the half-life (Thalf) of OHAS was significantly prolonged (by about 30 
minutes) in the combination. These changes resulted in a slight decrease in the 24 hour 
AUC of OHAS when in combination, although the AUC to infinity was not significantly 
changed. 
For the parent drug amodiaquine, a significant reduction in Cmax was noted when given 
together with AS. This 23.6% reduction in Cmax was reflected in a decrease in the 24-
hour AUC. The other parameters remained unchanged. Oesethylamodiaquine showed 
both an earlier Tmax (by 1.38 hours) and a reduced Thalf (by 107 hours) when given 
with artesunate. The Cmax and AUC (both parameters) remained unchanged. 
Graphs of these results are presented in Appendix 0-1 (summary graphs for AS, OHAS, 
AQ and d-AQ) and 0-3 (individual graphs). 
11.4 Safety: 
Table 4' Adverse events 
Subject Phase Drug Adverse event Duration Severity Conc. Study drug Continue 
meds involved? on study? 
E 2 AQ Abdominal cramps 24 hr mild y unlikely y 
M 2 AQ Dental infection 72 hr mod y unlikely y 
E 2 AQ Diarrhoea 5 hr mild n yes y 
E 2 AQ Diarrhoea 24 hr mild n unlikely y 
G 2 AQ Generalised flushing 4 hr mod n yes n 
A 2 AQ Headache 6 hr mild n possible y 
E 2 AQ Headache 5 hr mild n yes y 
p 2 AQ Headache 12 hr mild n possible y 
B 3 AQ Headache 12 hr mild n possible completed 
K 3 AQ Headache 4 hr mild n possible completed 
L 3 AQ Headache 12 hr mild n yes completed 
E 2 AQ nausea 5 hr mild n yes y 
G 1 AS Diarrhoea 14 hr mild n unlikely y 
M 1 AS Diarrhoea 6 hr mild n unlikely y 
B 1 AS Headache 12 hr mod n possible y 
B 1 AS nausea 12hrs mod n possible y 
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G 1 AS nausea 14 hr mild n unlikely y 
J 1 AS nausea 24 hr mild n unlikely y 
B 1 AS Vomiting 12 hr mod n possible y 
B 2 ASAO Abnormal taste 12 hr mild n possible y 
H 2 ASAO Depression ongoing mod y unlikely n 
B 2 ASAO Headache 12 hr mild n possible y 
K 2 ASAO Headache 4 hr mild n possible y 
A 3 ASAO Headache 3 hr mild n possible completed 
A 3 ASAO hepatitis 76 days severe n yes completed! 
K 2 ASAO nausea 4 hr mild n possible y 
K 2 ASAO nausea 10 hr mild n possible y 
A 3 ASAO nausea 3 hr mild n possible completed 
M 3 ASAO nausea 2hr mild n ssible com leted 
AS = artesunate Conc. meds = concomitant medication used. y= yes 
AO = amodiaquine mod. = moderate n = no 
Table 4 documents all the adverse events experienced during the study. All the events 
resolved spontaneously. A report has been submitted (attached as Appendix F) for the 
prolonged severe transaminitis, thought to be due to the study medication, experienced 
by subject A after phase 3 of the study. Subject A had the highest area under the 
concentration time curve for desethyl-amodiaquine, close to 3 times the mean, when 
administered in combination with artesunate in phase 3. There were no other liver 
function abnormalities detected in any other volunteers. No renal or electrolyte 
abnormalities were detected in any volunteers. 
One subject was withdrawn (subject G) due to generalised flushing of his face and body, 
which began 2 hours after a dose of amodiaquine alone and continued for 4 hours. 
Although there were no systemic symptoms associated with this flushing, the risk of this 
being a hypersensitivity reaction was too great for a second dose of amodiaquine to be 
risked. Another subject was withdrawn (subject H) due to the need for concomitant 
administration of fluoxetine for her pre-existing depression. The depression had been an 
intermittent problem for which she had sought therapy in the past, and was unlikely to 
have been due to the study medication. A further subject developed and intercurrent and 
probably unrelated dental infection. 
Overall, ten out of 15 subjects (66%) reported adverse events. This frequency was 8/15 
(53%) within 3 weeks of administration of amodiaquine alone. 4/15 (26.7%) within 6 days 
of administration of artesunate alone and 5/15 (33.3%) within 20 days of the 
combination. Gastrointestinal problems were the most commonly reported adverse 
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Table 5: Effect of treatments on baseline values - beta=estimate of average change in 
baseline values due to treatment. 
Haematological Sodium Sodium Artesunate Amodiaquine 
parameters Artesunate + Amodiaquine 
Beta(standard Beta(standard error) Beta(standard error) 
error) p-value p-value 
p-value 
Haemoglobin -0.634 (0.2928) -1.060 (0.5655) -0.718 (0.5507) 
P = .030 p = 0.061 P = 0.193 
i Haematocrit -0.006 (0.0098) -0.013 (0.0189) -0.003 (0.0184) 
p = 0.530 p = 0.493 P = 0.864 
• Platelet count -30.656 (10.9197) .. 38.3626 (21.0894) -50.8388 (20.5369) 
p = 0.005 p = 0.069 P = 0.013 
White cell count -1.635 (0.5) -3.168 (0.9657) -3.414 (0.9404) 
p = 0.001 p = 0.001 p = 0.000 
Neutrophils -0.998 (0.3604) -1.682 (0.696) -1.935 (0.6778) 
P =0.006 p = 0.016 p = 0.004 
Lymphocytes -0.540 (0.2661) -1.142 (0.5139) -1.130 (0.5) 
P = 0.042 P = 0.026 p = 0.024 
Two of the moderately severe adverse events (hepatitiS and hypersensitivity) were 
reported to the medicines regulatory authority in South Africa, the Medicines Control 
Council. 
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/12.0 Discussion and conclusions 
Pharmacokinetic profiles: 
this study has shown that there was a PK interaction between amodiaquine and 
artesunate. The clinical significance of this can be put into context from extensive clinical 
trials data which show that the combination is more effective than AQ alone (Adjuik et al 
2001). 
Of the 2 drugs and 2 major metabolites measured in this study only the rapidly 
metabolized parent drug artesunate experienced no changes in any of its 
pharmacokinetic parameters consequent to the addition of amodiaquine. The bulk of the 
artesunate would be metabolized by 1 hour after dosing; well before the Tmax of 
amodiaquine (at 2.38 hours) was reached. 
The kinetic profile of the major, and active, metabolite of artesunate, dihydroartemisinin 
was altered by co-administration with amodiaquine. The Cmax was significantly reduced, 
and the half-life was prolonged. Overall, there was a small, but significant decrease in 
total drug exposure as measured by the 24-hour AUC, although this difference was lost 
when AUC tb infinity was examined. 
On reviewing the PK parameters of the parent drug amodiaquine and its active 
metabolite desethylamodiaquine, it appears that the combination with AS resulted in a 
more rapid metabolism of AQ to D-AQ, as noted by a reduction in Cmax and a decrease 
in AUC of amodiaquine. An earlier Tmax and shorter Thalf for D-AQ (with AS), together 
with an unchanged Cmax and AUC confirm the more rapid conversion to D-AQ, without 
loss of total drug exposure. 
The significance of these changes in PK parameters on parasite killing is doubtful. 
Parasite killing is related to the time that the drug concentrations remain above the 
minimal parasiticidal concentration. For DHAS, the active metabolite of AS, the Cmax is 
probably the more important PK parameter because the half-life of AS is very short. 
Thus, the Significantly lower Cmax observed for the combination therapy could 
theoretically reduce to some extent the rate of parasite killing. For DAQ, the active 
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Appendix A: Study Protocol 
ARTESUNATE AND AMODIAQUINE: TOLERABILITY AND DRUG INTERACTION 
STUDY IN HEALTHY NORMAL VOLUNTEERS 
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In one trial combination therapy with artesunate and mefloquine caused a slightly higher 
incidence of vomiting than did treatment with either individual drug, but this difference 
was not statistically significant (Looaresuwan et ai, 1992). In larger studies, other 
investigators found the combination of artesunate and mefloquine was associated with a 
lower incidence of vomiting than mefloquine alone (Nosten et ai, 1994; Luxemburger et 
ai, 1994). Nausea and dizziness were more frequent in patients receiving mefloquine 
alone than in those receiving it in combination with artesunate (Luxemburger et ai, 
1994). These apparent differences in the incidence of 'adverse effects' may actually 
reflect the more rapid resolution of the symptoms of malaria in patients treated with the 
combination therapy (Looareesuwan et ai, 1994), rc;lther than the true incidence of drug-
related adverse effects with the different treatments. 
: 
In general, to date the artemisirin compounds have proven remarkable non-toxic in 
clinical practice. There has been no dose-related predictable adverse effect from 
therapy, even though a few clinicians remain concerned over central nervous system 
toxicity based on animal data. 
Dr Catherine Orrell <catherine.orrell@hiv-research.org.za> 
1 
rI.::>nIUl:ITI:\I.::><:: in 
.... "",.'\J<:IT"" .. " in 
(1 
{1 
{1 
(1 
in 
{1 
1 
1 -
1 
one 
1. 
1 
1 
• 
• 
• 
:lIB'J"f!!J'1I measures 
1 
4 
• 
• 
1 
Artesunate amodiaquine pharmacokinetic report. Page 68 of 137 
Table 1: 
Type of Compound Route Number of 
Patients 
Artemether Oral 863 
1m 2663 
Artemisinin Oral 1016 
1m 114 
Pr 1351 
Artesunate Oral 1742 
1m , 194 
Iv 989 
Pr 208 
Arteether 1m 50 
Dihidroartemisinin Po 51 
Total 9241 
1m: intramuscular Iv: intravenous Pr: per rectum 
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I Patient consent form 
Volunteer information 
ARrESUNATE AND AMODIAQUINE: TOLERABILITY AND DRUG INrERACTION 
STUDY IN HEALTHY NORMAL VOLUNTEERS 
Introduction- what this trial is about: 
Malaria is an illness transmitted by mosquitoes. Millions of people in Africa die of malaria 
every year. The infectious organism is a parasite. The one that affects South Africa is 
usually Plasmodium falciparum. Most malaria can be treated, particularly if diagnosed 
early on. However, the falciparum strain is rapidly becoming resistant to drugs commonly 
used to treat it, such as chloroquine. New drug development will not be able to keep up 
with this rising rate of resistance. 
Novel approaches are needed. One of these is to use two anti-malarials together. New 
drugs, to which Plasmodium Falciparum is still sensitive, can have their useful life 
prolonged by giving them with another anti-malarial. 
This trial is to look at the combination of amodiaquine, an old anti-malarial with a similar 
structure to chloroquine, and artesunate, a new, rapidly acting anti-malarial. These drugs 
have not been used in combination before. This trial aims to establish whether the two 
drugs interact at a biological level when taken together, and whether a single dose of 
both drugs taken together is tolerable to a patient. 
Duration of the trial: 
Screening for the trial will happen in the 3 weeks preceding the study. Should you be 
accepted for the trial and decide to take part in it, you will be involved for 48 days from 
the time of taking the first study dose. 
During these seven weeks you will spend 3 days (7am to 8pm) in a ward. These will be 
weekend days- days 0,7 and 28. On these days you will be given the study medicines to 
take in the morning. Another 19 blood specimens are needed, on non-ward days. Blood 
samples will be taken between 7hOO and 8h30 on the required days. 
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Trial structure and procedures: 
Screening: 
Before you are accepted for the trial you will need to be screened to check whether it is 
safe for you to take the study drugs. This screen will involve a full medical history and 
clinical examination. Your heart will be monitored with an electrocardiograph (ECG). 
Some blood (15ml) will be taken to check for liver and kidney function and blood cell 
counts. Your blood and a sample of urine will also be screened for drugs of abuse. If you 
are a woman a pregnancy test will be sent. 
You will not be accepted for the trial if: 
• any of the results are abnormal 
• you have been in a malarial area in the preceding 8 weeks 
• you smoke (more than 5 a day) or drink heavily (more than 1 unit a day) 
• you are pregnant 
• you have any medical disorders or are taking any medications 
• you do not agree to the trial regulations and to return for all the follow-up evaluations 
and blood specimens 
If any abnormalities ,are found during the screening the trial doctor will explain these to 
you and refer you to the appropriate doctor as necessary . 
. You will be asked not to take'any other.medicines; drugs OR ALCOHOL for· the duration 
of the trial. 
Trial days: 
See Trial Schedule table. 
Once you have been accepted for the trial you will be asked to arrive at ward G13, 
Groote Schuur at 7am on day O. It is important that you do not eat or drink anything 
from midnight the night before. 
When you arrive you will be given a bed and a cannula (a thin plastic tube over a 
needle) will be inserted in your arm. This can be slightly painful at the time of insertion. 
Once the needle is removed and the plastic tube left in place it may feel uncomfortable, 
but should not cause pain. Blood can be taken through the cannula without any further 
pricks with a needle. If the cannula blocks it may be necessary to resite It or take the 
blood using a needle and syringe. You may end up with a bruise at the site of cannula 
insertion. 
You will be asked to stay in your bed until after breakfast at 10am. No food or drink is 
allowed until breakfast. After breakfast you may drink water and after lunch (1 pm) you 
may eat and drink fluids freely. Supper will be between 6 and 7pm. All these meals are 
standardised. 
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At 8am you will be given the first dose of the study drugs. On the first day everyone will 
take artesunate. In order to monitor the drug levels in the blood, samples (15 ml) will be 
taken through the cannula 12 times in the day. Artesunate has a short half-life and all the 
drug should be gone by 12 hours. The last specimen for the day will be taken at 8pm, 
after which you can leave. 
Six days after you take the artesunate safety bloods (to check liver and kidney functions, 
as well as blood cell counts) will be taken. 
Day seven is the second admission day .. It is important that you do not eat or drink 
anything from midnight the night before. This day is the same as day O. The drugs 
taken will either be a dose of amodiaquine alone or a dose of amodiaquine with a dose 
of artesunate. Amodiaquine has a half-life of up to 3 weeks, so although the artesunate 
is gone by 12 hours we need to monitor the amodiaquine for longer. 
After this round we need to take bloods the following morning and on days 2,3,4,5, 7 10, 
14 and 20 after taking the drug. On the 20th day safety bloods will be taken too. 
The third admission day follows. It is identical to the previous two. Again, it is important 
that you do not eat or drink anything from midnight the night before. You will 
receive the treatment (either amodiaquine alone or a dose of amodiaquine with a dose of 
artesunate) that you did not get the previous round. All the blood samples in the ward 
and for the 3 weeks afterwards are the same as above. The last specimen is on the 20th 
day after your last drug dose. 
Your rights as a volunteer: 
Your participation is completely voluntary. You can refuse to participate and withdraw at 
any time without stating a reason. The trial investigator retains the right to withdraw you 
from the study if it is considered important for your safety. If it is discovered you did not 
give an accurate history or did not follow the trial regulations you may also be withdrawn. 
Risks of the trial: 
Both of the trial drugs have the potential to cause side effects. Allergies or unexpected 
side effects may occur. 
Dr Catherine Orrell <catherine.orrell@hiv-research.org.za> 
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Trial Schedule 
Day 
Action 
Pre-trial screening Examination, screening blood samples-, 
ECG, urine sample, pregnancy test for 
women. 
Day prior to day 0 NIL BY MOUTH OVERNIGHT 
Day 0 (Saturday) Artesunate dose Admit to ward 7am to 8pm. Cannula, 12 x 
blood samples, ECG 
Day 6 (Friday) Safety blood samples-
NIL BY MOUTH OVERNIGHT 
I Day 7 (Saturday) Amodiaquine or artesunate Admit to ward 7am to 8pm. Cannula, 12 x 
! and amodiaquine blood samples, ECG 
Day 8 (Sunday) Drug blood sample 8am 
Day 9 (Monday) Drug blood sample 8am 
Day 10 (Tuesday) Drug blood sample 8am 
Day 11 (Wednesday) Drug blood sample 8am 
Day 12 (Thursday) blood sample 8am 
Day 14 (Saturday) Drug blood sample 8am 
Day 17 (Tuesday) Drug blood sample 8am 
Day 21 (Saturday) Drug blood sample 8am 
Day 27 (Friday) Drug and safety blood samples-
NIL BY MOUTH OVERNIGHT 
Day 28 (Saturday) Amodiaquine or Admit to ward 7am to 8pm. Cannula, 12 x 
artesunate and amodiaquine blood samples, ECG 
. Day 29 (Sunday) Drug blood sample 8am 
. Day 30 (Monday) Drug blood sample 8am 
Day 31 (Tuesday) Drug blood sample 8am 
Day 32 (Wednesday) Drug blood sample 8am 
Day 33 (Thursday) Drug blood sample 8am 
Day 35 (Saturday) Drug blood sample 8am 
Day 38 (Tuesday) Drug blood sample 8am 
Day 42 (Saturday) Drug blood sample 8am 
Day 48 (Friday) Drug and safety blood samples-
- Safety and screening bloods involve two tubes: one for a full blood count, and one for 
liver and kidney functions. 
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Patient consent form 
ARTESUNATE AND AMODIAQUINE: TOLERABILITY AND DRUG INTERACTION 
STUDY IN HEALTHY NORMAL VOLUN"rEERS 
Patient name (last and first- please print): _____________ _ 
Date of birth (day/month/year): 
Patient/trial number: 
I confirm that I have been fully informed by Dr. ____________ _ 
about the nature, schedule and risks of this clinical trial with artesunate and 
amodiaquine. I have also received, read and understood the patient information 
regarding the clinical trial. 
I am aware that results of the trial will be published. I will in no way be identified in the 
publication. 
I may withdraw from the trial at any stage. 
I have had enough time and opportunity to ask questions. I am willing to participate, 
voluntarily, in this trial. 
Patient's name: 
Patient's signature: __________ Date: ______ _ 
I , Dr. confirm that the above patient has been 
fully informed of the nature, conduct, schedule and risks of the above trial. 
Investigator's signature: __________ Date: ______ _ 
Witness name (print): 
Witness signature: __________ Date: ______ _ 
Dr Catherine Orrell <catherine.orrell@hiv-research.org.za> 
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I Appendix B: Randomization table 
(as used for statistical analysis) 
The three drug administrations were organised according to the following randomisation 
table. 
'~® ~~ ~c$ ... , .~rul, ... 
;':/",," ;.- , .. 
" 
. ':','if,,:;/ir:,' ,"/'''' !'f!$!l!I'{ ,.;: .. : ',J, ~ 
A 1 3 2 
B 1 2 3 
C 1 3 2 
0 1 2 3 
E 1 3 2 
F 1 2 3 
J 1 3 2 
K 1 2 3 
L 1 2 3 
M 1 3 2 
N 1 2 3 
P 1 3 2 
Q 1 3 2 
1 = Sodium Artesunate alone Phase 1 
2 = Sodium Artesunate + Amodiaquine base} 
Phase 2 and 3 
3 = Amodiaquine base alone 
Dr Catherine Orrell <catherine.orrell@hiv-research.org.za> 
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I Appendix C: Normal laboratory ranges. 
Full blood count: 
Haemoglobin - women 
Haemoglobin - men 
Haematocrit - women 
Haematocrit - men 
Platelets 
White cell count 
Neutrophils 
Lymphocytes 
Chemistry: 
Sodium 
Potassium 
Urea 
Creatinine 
Total bilirubin 
AST 
ALT 
11.6 -15.6 g/dL 
13.3 -17.3 g/dL 
0.32 - 0.48 ratio 
0.37 - 0.53 ratio 
150 - 450 x109/L 
4.0 -11.0 X109/L 
1.8 - 7.7 x109/L 
1.0 - 4.0 x109/L 
135 -145 mmollL 
3.5 - 5.5 umol/L 
1.7 - 6.7 umol/L 
75 -115 umol/L 
1 -17 umol/L 
1 - 25 units/L 
1 - 25 units/L 
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I Appendix 0-1: Pharmacokinetic summary tables and graphs 
• • 
suS'eel:1 - Tmax Cmax Half-life [ "]' J 1- - . , II ., ' 
I , (h) (ng/ml) (h) , II I , 
~-"'~ - --- .. - - " 
Art Amo+Art Art Amo + Art Art Amo+Art 
A 1.00 0.50 74.60 12.00 0.91 MD 
B 0.25 1.50 114.50 22 .60 0.15 MD 
C 0.50 0.50 279 .80 265.70 0.22 0.31 
D 0.25 0.25 56.70 336 .90 MD 0.52 
E 1.00 0.50 95.00 203 .80 MD 0.34 
F 0,50 0.75 253.40 21 .90 0.72 EXCL 
J 1.00 1.50 75.90 50 .60 MD 0.84 
K 0.75 1.00 388.00 182.40 0.16 0.52 
L 0.50 1.50 557 .00 105.20 0.44 0.53 
M 0.25 0.50 332.60 283.00 0.75 0.81 
N 0.50 0.50 389.40 96.50 0.45 0.55 
P 0.75 0.50 252.70 174.50 0.28 0.26 
Q 0.75 MD 143.20 MD 0.34 MD 
Mean 0.62 0.79 231 .8 146.3 0.44 0.52 
SEM 0.08 1.09 42 .99 32.19 0.08 0.07 
95%CI 0.44-0 .78 0.50-1.09 138.1-325.4 75.4-217.1 0.25-0.63 0.36-0.68 
Paired t-test (two-tailed p-value) 
0.25 nsd 0.12 nsd 0.08 nsd 
Wilcoxon matched pairs signed rank (two-tailed p-value for normal approximation) 
0.36 nsd 0.09 
. . Abbreviations: Art = Sodium Artesunate 
AUC = Area under the concentration-time curve 
MD = missing or incalculable data 
nsd 0.06 nsd 
Amo - Amodiaquine base 
nsd = no significant difference 
EXCL = excluded data (F Thalf >6 h) 
b 
, 
• b • Ik • 
AUC (O-Iast time point) AUC (O-inf) 
(ng.h/ml) (ng.h/ml) 
." 
Art Amo + Art Art Amo+Art 
66.15 28.50 94.64 MD 
39.28 27.80 40.44 MD 
137.30 158.33 138.02 157.74 
17.18 259.06 MD 262.12 
65.88 111.74 MD 111 .65 
152.85 54.98 169.24 162,66 
50 .31 69.20 MD 77.79 
158.08 171.98 157.83 184.42 
233.76 96.08 235.31 99.32 
264 .59 324 .74 265.60 332.83 
271 .11 79 .13 272.95 82 .58 
222.54 93.31 221 .39 94 .77 
87.26 MD 87.12 MD 
135.9 122.9 168.3 156.6 
24.76 26.40 25.19 26.63 
81 .93-189 .8 64 .79-181 .0 111 .3-225.2 96.35-216.8 
0.62 nsd 0.25 nsd 
0.73 nsd 0.47 nsd 
Cmax - peak plasma concentration 
sd = significant difference 
b • • 
SUbJe~'FI'~"- -:. - " -T:ma'x 4 fl!rl , - - Ciifcl'x - . - Haff~life - i' AOC " (o-!a~nime . pOintY , . , 
1 ~ I .' , , , . (ng:h/ml). . ' JIi) (hg/ml) ·m) • I ". , , 
~i!!1L._._ !,J"4_"o 1:11:. •• ' I. 1_ ' to. i ___ ,j) .... 1 . - " , .. I --.... '.1'l-~ . J ~ ,,' 
" 
, 
-
-
Art Amo + Art Art Amo + Art Art Amo + Art Art Amo + Art 
A 0.75 1.50 971 .00 458.20 1.16 1.73 1825.50 1351.13 
8 0.50 0.75 592 .10 296.30 1.54 2.80 943.21 916.61 
C 0.75 0.50 1114.70 526.80 0.78 1.90 1326.75 778.64 
0 3.00 0.50 364.30 1072.90 1.05 0.85 1173.51 1543.81 
E 1.50 0.75 443.50 456.80 0.88 0.99 588.11 684.33 
F 0.75 4.00 1042.10 243.70 1.27 MD 1315.43 609.35 
J 1.00 3.00 560.30 217.80 1.20 1.49 1066.26 758.25 
K 0.75 1.50 1336.50 508.10 1.05 2.25 1104.86 1250.56 
L 0.50 1.50 1201 .20 459.50 1.02 1.18 1677.69 708.66 
M 0.75 0.75 835.50 701.90 1.22 1.42 1320.01 1428.88 
N 0.75 2.00 855.30 197.80 1.04 1.76 1523.51 607.63 
P 0.75 0.75 590.70 416.90 0.77 0.86 1264.93 749.08 
Q 1.00 3.00 1070.90 243.70 1.55 MD 1594.36 655.04 
Mean 0.98 1.58 844.5 446.2 1.12 1.56 1286 926.3 
SEM 0.18 0.31 85.83 66.41 0.07 0.18 91 .23 94.14 
95%CI 0.58-1.38 0.90-2 .26 657.5-1031 301 .5-590.9 0.97-1 .27 1.16-1.97 1088-1485 721.2-1131 
Paired t-test (two-tailed p-value) 
0.16 nsd 0.007 sd 0.008 sd 0.02 sd 
Wilcoxon matched pairs signed rank (two-tailed p-value for normal approximation) 
0.1 2 
Abbreviations: 
2005 
nsd 0.01 sd 
Art = Sodium Artesunate 
Cmax = peak plasma concentration 
nsd = no significant difference 
MD = missing or incalculable data 
0.01 sd 0.03 
Amo = AmodiaqUine base 
AUC = Area under the concentration-time curve 
sd = significant difference 
sd 
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• • • 
-AUC' (O-IM) 
(ng.h/ml) 
.. _. 
-
Art Amo + Art 
1821.63 1370.41 
1041.91 1057.98 
1331.94 916.15 
1167.60 1546.46 
591.28 689.43 
1339.55 MD 
1061 .54 760.04 
1111.10 1281 .03 
1694.08 731.98 
1317.20 1429.40 
1517.50 745.74 
1266.21 751.89 
1597.17 MD 
1297 1026 
89.37 97.91 
1102-1492 807.3-1244 
0.09 nsd 
0.15 nsd 
• • • • [ 6!eCl ~ Tmax crriax Half-life AUC '(O-Iast time' point) 
(h) (ng/ml) (h) (ng.h/ml) 
- _ [,--
-
- - .' 
-
Amo Amo + Art Amo Amo + Art Amo Amo+Art Amo Amo + Art 
A 3.00 3.00 38.814 27.132 4.591 4.205 287.227 199.129 
B 4.00 1.50 19.455 11 .744 4.499 MD 173.368 55.191 
C 1.50 1.00 9.298 14.038 1.60 4.967 20.377 65.327 
D 3.00 1.50 28.236 39.54 2.575 5.006 114.321 217.136 
E 3.00 2.00 26.25 22.175 MD MD 62.747 31.121 
F 0.75 4.00 29.95 13.20 1.628 MD 51.364 61.162 
J 3.00 2.00 27.58 24.57 13.804 2.873 252.824 113.667 
K 1.50 3.00 46.822 18.281 10.822 2.811 248.954 140.939 
L 2.00 2.00 30.049 24.676 4.445 3.91 219.352 158.082 
M 4.00 1.00 37 .684 36 .642 3.70 4.762 299.094 163.493 
N MD MD MD MD MD MD MD MD 
P 0.75 0.75 21.371 16.066 3.516 3.048 72 .039 69.069 
Q 2.00 0.75 44.57 26.771 2.669 2.923 251.368 100.39 
Mean 2.38 1.88 30 .01 22.90 4.90 3.83 171.10 114.60 
SEM 0.33 0.29 3.10 2.57 1.17 0.31 29 .29 17.56 
95%CI 1.66-3.09 1.23-2 .52 23.18-36.83 17.25-28.55 2.29-7.50 3.11-4.56 106.6-235.5 75.92-153.2 
Paired t-test (two-tailed p-value) 
0.33 nsd 0.04 sd 0.38 nsd 0.04 sd 
Wilcoxon matched pairs signed rank (two-tailed p-value for normal approximation) 
0.36 
.. Abbreviations: 
5/31/2005 
nsd 0.03 sd 
Art - Sodium Artesunate 
Cmax = peak plasma concentration 
nsd = no significant difference 
MD = missing or incalculable data 
0.73 nsd 0.04 
Amo - Amodiaquine base 
AUC = Area under the concentration-time curve 
sd = significant difference 
sd 
ag 80 ct 137 
• • 
AUC' (O-irif)" 
(ng .h/ml) 
Amo Amo + Art 
292.959 199.582 
176.221 MD 
24.131 89 .947 
125.872 223.933 
MD MD 
50.239 MD 
547.658 123.821 
340.447 99.898 
222.37 156.31 
293.332 205.156 
MD MD 
114.332 79.451 
244.056 102.618 
221 .10 142.30 
44.95 18.45 
120.9-321 .2 99 .77-184.8 
0.09 sd 
0.10 nsd 
• • • r:bi: ct _ Tmax Cmax Half-life (h) (ng/ml) (h) 
Amo Amo + Art Amo Amo+Art Amo Amo + Art 
A 3.00 3.00 324.65 327.14 219.19 266.86 
B 4.00 4.00 227.18 267.10 165.21 29.46 
C 3.00 1.00 155.86 178.04 106.98 168.99 
D 3.00 1.50 223.03 458.70 579.79 144.11 
E 3.00 2.00 324.91 657.72 207.71 190.84 
F 6.00 4.00 163.51 201.32 121 .23 99.49 
J 3.00 2.00 300.42 266.61 282.10 141.01 
K 8.00 3.00 256.67 260.64 427.68 133.24 
L 2.00 2.00 329.40 261 .29 203.23 79.28 
M 4.00 1.50 371.48 493.38 129.71 184.93 
N MD MD MD MD MD MD 
P 1.50 1.50 271.27 112.40 245.03 96.96 
Q 3.00 1.50 332.00 158.02 216.57 92.25 
Mean 3.63 2.25 273.40 303.50 242.00 135.60 
SEM 0.51 0.29 20.05 45.76 39.44 18.06 
95%CI 2.50-4.75 1.61-2.89 229.2-317.5 202.8-404.2 155.2-328.8 95.87-175.4 
Paired t-test (two-tailed p-value) 
0.007 sd 0.49 nsd 0.03 sd 
Wilcoxon matched pairs signed rank (two-tailed p-value for normal approximation) 
0.007 sd 0.52 
.. Abbreviations: Art - Sodium Artesunate 
AUC = Area under the concentration-time curve 
MD = missing or incalculable data 
5/31/..:005 
nsd 0.03 sd 
Amo = Amodiaquine base 
nsd = no significant difference 
• 
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• • 
AUC (O-Iast time point) AUG (O-inf) 
(ng.h/ml) (ng.h/ml) 
Amo Amo+Art Amo Amo+Art 
12526.89 29497.83 14590.04 42443.15 
11194.30 3571.432 13330.31 4092.886 
7284.21 7550.05 8001.973 8565.872 
10927.82 8349.786 19765.85 9270.824 
10650.79 16126.56 12456.83 17921.34 
14678.67 8289.724 15698.35 9563.785 
9962.464 8457.925 12284.74 9433.391 
19254.30 14365.29 26327.09 15192.44 
11408.59 5858.69 13496.02 6432.519 
10761.65 14049.74 12223.65 15214.01 
MD MD MD MD 
16352.65 7967.574 21295.58 8787.827 
10865.24 3774.60 14107.30 4420.213 
12160 10650 15300 12610 
920.80 2066.00 1421.00 2978.00 
10129- 6108-15202 12170- 6056-19167 
14182 18426 
0.49 nsd 0.43 nsd 
0.23 nsd 0.15 nsd 
Cmax = peak plasma concentration 
sd = significant difference 
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Amodiaquine Summary 
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I Appendix 0 .. 2: All individual PK data 
Artesunate: 
,Subject Time Artesunate only Artesunate + Subject Time Artesunate only Artesunate + 
Amodiaquine Amodiaquine 
t 'u" (hrs) Art Dihydro Art Dihydro . " (hrs) Art Dihydro Art Dihydro 
(ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) 
A 0 0 0 0 0 E 0 0 0 0 0 
A 0.25 0 0 0 0 E 0.25 0 0 0 0 
A 0.5 12 125.2 12 17.9 E 0.5 62.7 73.2 203.8 400.9 
A 0.75 12 971 12 126.5 E 0.75 34.3 159.7 115.2 456.8 
A 1 74.6 919 12 86.6 E 1 95 306.9 45.3 219.8 
A 2 12 739.2 12 458.2 E 2 12 443.5 12 161.2 
A 3 34.9 449.5 MD MD E 3 0 147.8 12 148.5 
A 4 0 214.4 MD MD E 4 0 40.2 0 98.6 
A 6 0 78.6 0 167.8 E 6 0 12 0 48.6 
A 8 0 65.9 0 50.2 E 8 0 12 0 12 
A 12 0 12 0 39.1 E 12 0 0 0 0 
A 24 0 0 0 0 E 24 0 0 0 0 
8 0 0 0 0 0 F 0 0 0 0 0 
8 0.25 114.5 85.2 0 0 F 0.25 24.2 12 0 0 
8 0.5 30.6 592.1 0 0 F 0.5 253.4 798.6 0 0 
-8' .. 0.75 12 432.9 12 296.3 F 0.75 51.5 1042.1 21.9 41.9 
8 1 0 328.3 12 207.7 F 1 79.2 726 12 39.2 
8 2 0 179.8 22.6 137.8 F 2 36.3 320.1 12 88 
8 3 0 81.2 12 177.8 F 3 30.3 224.4 MD MD 
8 4 0 271 0 142.5 F 4 0 115.5 12 104.5 
8 6 0 80.5 0 217.8 F 6 0 52.1 12 243.7 
8 8 0 0 0 46.6 F 8 0 29 0 0 
8 12 0 0 0 0 F 12 0 0 0 0 
8 24 0 0 0 0 F 24 0 0 0 0 
C 0 0 0 0 0 J. 0 0 0 0 0 
C 0.25 95 12 77.9 14.6 J 0.25 0 51.4 0 0 
-c ~ .. 0.5 279.8 841.5 265.7 526.8 J 0.5 12 60.6 28.6 57.3 
C 0.75 116.8 1114.7 123.8 480.2 J 0.75 12 96.3 12 74.6 
C 1 22.4 635.6 70.6 467.5 J 1 75.9 560.3 34 107.2 
C 2 12 405.9 12 42.3 J 2 31.7 339.2 50.6 197.8 
C 3 0 272.6 12 164.5 J 3 0 35.1 12 212.5 
C 4 0 126.7 0 84.6 J 4 0 258 12 217.8 
C 6 0 41.5 0 79.2 J 6 0 162.3 0 77.2 
C 8 0 0 0 0 J 8 0 27.7 0 28.6 
C 12 0 0 0 0 J 12 0 17.1 0 12 
C 24 0 0 0 0 J 24 0 0 0 0 
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Subject Time Artesunate only Artesunate + Subject Time Artesunate only Artesunate + 
Amodiaquine Amodiaquine 
(hrs) Art I D;hydro Art I Dihydro (hrs) Art Dihydro Art Dihydro 
(ng/ml) (nglml) (nglml) (nglml) (nglml) (nglml) (nglml) (nglml) 
D 0 0 0 0 0 K 0 0 0 0 0 
D 0.25 56.7 0 336.9 246.4 K 0.25 0 0 0 0 
D 0.5 12 196.6 309.7 1072.9 K 0.5 153.1 95.7 65 62.6 
D 0.75 0 153.1 179.1 969 K 0.75 388 1336.5 63.7 178.5 
D 1 0 207.9 23.3 679.3 K 1 44.8 650.7 182.4 463.5 
> D 2 0 142.5 45.8 432.9 K 2 12 445.5 69.9 508.1 
D 3 a 223.7 12 305.2 K 3 a 169.6 48.6 421.5 
D 4 a 364.3 12 163.8 K 4 a 76.5 0 169.8 
-0 6 0 167.6 0 55.9 K 6 0 34.9 0 84.6 
D 8 0 58.7 a 12 K 8 0 12 0 37.9 
D 12 0 12 a a K 12 a 0 0 24.6 
D 24 0 a a 0 K 24 a 0 a a 
L a a a 0 a 0 a a a - a 
·L 0.25 175.6 97 a a 0 0.25 a a - a 
L 0.5 557 1201.2 12 54.12 0 0.5 58.7 82.5 - 47.3 
, L . 0.75 87.1 1005.2 23.3 50.6 Or 0.75 143.2 1058.9 - 161.9 
",···L·, ' 1 36.9 742.5 24.6 62.6 0 1 58.1 1070.9 Spoilt 183.1 
I,', L 2 12 403.9 105.2 459.5 '0 2 12 546.1 Data 100.6 
L 3 12 442.2 17.9 256.4 ,,·0, " 3 12 344.3 - MD 
- a 124 12 104.5 L 4 0 4 a 179.1 - 243.7 
L 6 0 64 a 43.9 0 6 a 71.9 - 85.9 
L 8 a 34.9 a 33.3 0 8 a 26.6 - a 
L 12 0 a a a 0 12 a 12 - 0 
L 24 0 a 0 a 0 24 a a - a 
M a a a a 0 I 
M 0.25 332.6 598.6 227.1 160.5 l 
M 0.5 139.2 633.6 283 698.6 I ( 
M 0.75 90.4 835.5 279 701.9 
M 1 69.3 756.3 192.5 617.4 
M 2 12 37.2 42.6 416.2 
M 3 75.2 285.7 29.3 246.4 
M 4 17.8 146.5 12 147.2 
M 6 11.9 53.4 a 97.2 
M 8 a 12 a 42.6 
M 12 0 12 0 12 
M 24 0 a 0 a 
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N 0 0 0 0 0 
N 0.25 0 0 39.9 71.9 
N 0.5 389.4 475.2 96.5 137.2 
N 0.75 237.6 855.3 68.6 165.2 
N 1 166.3 793.3 16.6 41.2 
N 2 62 593.3 25.3 161.8 
N 3 12 376.8 12 197.8 
N 4 12 147.2 0 134.5 
N 6 0 71.3 0 89.9 
N 8 0 12 0 0 
N 12 0 12 0 0 
N 24 0 0 0 0 
p' 0 0 0 0 0 
p 0.25 62 45.5 12 26.4 
P 0.5 212.5 281.1 174.5 243 
P 0.75 252.7 590.7 93.9 416.9 
P 1 MD MD 45.9 279 
.. 
2 29.7 585.6 12 209.8 P 
p 3 12 437.5 0 142.5 
.p 4 0 151.8 0 131.2 
P 6 0 12 0 70.6 
P 8 0 12 0 12 
P 12 0 0 0 0 
.P 24 0 0 0 0 
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Amodiaquine: 
Time Amodiaquine Amodiaquine + Time Amodiaquine Amodiaquine + 
Subject only Artesunate Subject only Artes u nate 
(hrs) Amo~ Amo O-Amo (hrs) Amo O-Amo Amo O-Amo (ng/ml) (ng/mlJ (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) 
A 0 0 0 0 0 C 0 0 0 0 0 
A 0.25 0 0 0 - C 0.25 0 0 0 0 
A 0.5 0 0 7.2 5.11 C 0.5 0 0 0 0 
A 0.75 0 0 6.62 4.86 C 0.75 0 12.09 11.99 76.28 
A 1 31.02 10.21 - - C 1 5.23 15.52 14.04 178.04 
A 1.5 15.35 33.79 15.07 61.07 C 1.5 9.3 100.7 9.82 173.26 
A 2 37.99 107.1 17.8 127.78 C 2 5.99 142.17 9.18 163.11 
A 3 38.81 324.65 27.13 327.14 C 3 4.64 155.86 10.28 137.57 
A 4 22.2 256.79 24.41 317.94 C 4 - 106.33 7.78 125.51 
A 6 23.13 237.67 14.06 198.05 C 6 0 104.52 - 115.75 
A 8 15.81 181.75 8.19 152.66 C 8 0 111.77 - 77.88 
A 12 9.2 168.64 6.85 180.63 C 12 0 79.45 0 77.32 
A 24 0 94.05 0 105.46 C 24 0 45.65 0 39.68 
A 48 54.39 68.7 C 48 38.65 25.49 
A 72 35.01 71.33 C 72 22.23 16.86 
A 96 29.44 74.67 C 96 22.72 19.56 
A 120 27.64 36.9 C 120 18.92 15.55 
A 168 16.7 81.84 C 168 11.98 15.74 
A 240 14.62 53.81 C 240 13.95 10.39 
A 336 9.22 50.21 C 336 4.65 8.07 
A 480 6.52 33.62 C 480 - 4.17 
B 0 0 0 0 0 0 0 0 0 0 0 
B 0.25 0 - 0 0 0 0.25 0 0 13.89 0 
B, 0.5 0 - 0 0 0 0.5 0 0 30.45 343.47 
B 0.75 - - 9.32 - 0 0.75 24.13 10.81 23.47 170.22 
a 1 11.67 - 5.84 4.77 0 1 6.19 9.83 24.26 410.4 
B 1.5 10.95 15.45 11.74 10.62 0 1.5 8.501 22.92 39.54 458.7 
B 2 12.01 71.9 9.33 50.29 0 2 6.62 39.01 28.05 334.29 
B 3 17.27 185.32 10.35 151.07 D 3 28.24 223.03 19.14 245.87 
B 4 19.46 227.18 10.98 267.1 D 4 16.63 91.47 20.76 151.18 
B 6 15.09 201.59 14.06 131.13 0 6 - 111.42 12.64 134.04 
B 8 9.99 179.01 0 137.28 0 8 6.74 90.08 10.08 131.55 
B 12 5.81 131.74 0 69.88 0 12 0 96.51 5.56 96.77 
B 24 0 74.55 0 40.7 0 24 0 53.91 0 66.12 
B 48 44.23 28.19 0 48 43.31 34.5 
B 72 34.27 - 0 72 35.49 25.47 
B 96 27.12 0 0 96 36.67 15.84 
B 120 22.32 0 0 120 29.8 16.88 
B 168 18.25 0 0 168 16.52 11.67 
B 240 7.37 0 0 240 14.08 5.72 
B 336 13.04 0 0 336 12.56 4.67 
B 480 8.96 0 D 480 10.57 4.43 
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Time Amodiaquine Amodiaquine + Time Amodiaquine Amodiaquine + 
Subject only Artesunate .Subiect onlY Artesunate 
(hrs) Amo D~Amo Amo D-Amo (hrs) Amo D-Amo Amo 
(ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (. ."" -, "~ I 
E 0 0 0 0 0 J 0 0 0 0 0 
E 0.25 0 0 0 0 J 0.25 11.82 0 0 0 
E 0.5 0 0 0 0 J 0.5 19.35 0 5.86 0 
E 0.75 0 0 9.35 185.24 J 0.75 18.78 5.54 14.47 -
E 1 0 66.03 12.99 550.83 J 1 18.58 12.33 11.21 3.86 
E 1.5 14.033 220.81 14.56 399.22 J 1.5 21.04 41.48 21.86 69.34 
E 2 17.34 280.16 22.17 657.72 J 2 23.22 120.2 24.57 266.61 
E 3 26.25 324.91 0 224.4 J 3 27.58 300.42 16.48 253.67 
.. ~ '.E 4 10.98 218.29 0 288.44 J .. " 4 20.52 261.02 15.38 241.92 
~. E 6 0 179.53 0 220.99 . J 6 21.22 200.72 8.87 209.76 
E 8 0 178.96 0 223.57 J 8 25.01 171.05 - 163.72 
E 12 0 149.38 0 171.58 J 12 14.81 151.1 0 161.68 
E 24 0 66.96 0 122.61 J 24 - 74.64 0 77.97 
E 48 56.8 78 J 48 37.3 31.52 
E 72 39.31 50.86 J 72 31.38 24.71 
E 96 20.48 47.95 J 96 21.59 22.97 
E 120 18.03 29.01 J 120 13.73 13.79 
E 168 13.93 24.22 J 168 12.88 11.09 
E 240 9.92 15.6 J 240 9.87 -
E 336 6.72 10.92 J 336 8.45 4.8 
E 480 6.03 6.52 J 480 5.71 -
F 0 0 0 0 0 K 0 0 0 0 0 
F 0.25 10.53 0 0 0 K 0.25 0 0 0 0 
F 0.5 22.53 6.89 0 0 K 0.5 14.29 12.3 2.69 0 
·F· . 0.75 29.95 65.33 0 0 K 0.75 11.9 33.62 12.33 4.98 
F 1 10.03 112.42 0 0 K .< 1 7.93 57.87 9.4 12.3 
F 1.5 7.6 109.53 0 0 K 1.5. 46.82 89.39 7.72 62.54 
F 2 - 122.72 7.11 4.02 K 2 17.96 154.07 15.76 222.44 
.r: 3 7.46 126.55 5.7 34.58 K 3 18.28 182.57 18.28 260.64 
F 4 - 132.45 13.2 201.31 K 4 15.99 179.59 11.13 219.7 
F 6 - 163.51 7.58 156.95 K 6 18.66 238.31 8.3 176.81 
F 8 0 95.23 - 129 K 8 - 256.67 - 135.25 
F 12 - 126.46 0 99.39 K 12 9.52 219.71 - 141.29 
F 24 0 84.89 0 65.91 K 24 0 174.73 0 141.44 
F 48 39.73 K 48 97.09 75.041 
F 72 37.31 22.92 K 72 83.98 34.79 
F 96 31.32 17.32 K 96 62.51 37.41 
F 120 25.59 21.67 K 120 41.9 13.85 
F 168 34.87 13.21 K 168 18.79 24.54 
F 240 26.49 4.951 K 240 17.2 15.5 
F 336 18.53 6.01 K 336 14.23 16.83 
F 480 5.83 8.88 K 480 11.46 4.3 
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Time Amodia~iaqUine+ I Time I Amodiaquine Amodiaquine + 
Subject only Artesunate' - _. onlY Artesunate 
(hrs) Amo D-Amo D-Amo Amo D-Amo Amo D-Amo 
(ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) 
L 0 0 0 0 0 p 0 0 0 0 0 
L 0.25 0 0 0 0 P 0.25 8.37 4.63 0 0 
L 0.5 12.07 5.17 0 0 P 0.5 15.31 5.46 0 0 
L 0.75 10.52 7.29 0 0 P 0.75 21.37 97.71 16.07 14.9 
L 1 21.51 21 11.82 0 P 1 19.46 213.73 15.87 67 
L 1.5 29.54 179.58 11.8 24.2 P 1.5 18.48 271.27 9 112.4 
L 2 30.05 329.4 24.68 261.29 P 2 17.58 267.56 7.28 102.14 
L 3 23.51 272.44 23.36 240.78 >. P 3 15.48 195.28 6.93 103.51 
L 4 25.6 230.79 17.92 154.45 ,p 4 10.38 169.88 10.75 107.61 
L 6 11.89 163.06 9.91 139.75 P 6 0 124.22 6.54 108.88 
.L 8 8.03 134.02 6.55 113.66 P 8 0 145.87 4.33 76.72 i 
L 12 7.32 149.01 4.94 74.35 P 12 0 103.74 0 88.08 
L 24 0 58.7 0 53.9 P 24 0 73.88 0 54.56 
·L 48 50.39 32.52 P 48 52.89 36.06 
L 72 22.56 20.09 P 72 51.71 27.98 
L 96 21.14 13 P 96 46.63 22.08 
L 120 22 11.28 P 120 31.56 17.29 
L 168 20.18 7.99 P 168 31.61 17.32 
L 240 16.43 - P 240 30.78 7.2 
L 336 10.93 5.02 P 336 19.66 5.43 
L 480 7.12 - P 480 13.98 5.86 
M 0 0 0 0 0 Q 0 0 0 0 0 
M 0.25 0 0 12.15 0 Q 0.25 5.93 0 11.7 0 
M 4 0.5 0 0 30.58 17.68 Q 0.5 7.1 0 24.2 4.86 
.M 0.75 5.22 0 36.56 131.45 Q 0.75 22.53 - 26.77 44.02 
M 1 17.88 0 36.64 416.19 Q 1 33.13 6.82 20.02 101.47 
M 1.5 28.98 10.75 28.51 493.38 Q 1.5 32.1 39.8 18.39 158.02 
M 2 15.84 47.31 28.21 479.96 Q 2 44.57 69.31 14.2 129.1 
M ? 3 30.05 293.93 17.93 261.59 Q' 3 41.26 332 11.08 111.04 
M 4 37.68 371.48 16.33 261.54 .. Q 4 19.06 185.77 10.29 87.48 
M 6 26.78 213.27 13.21 251.49 Q 6 29.73 146.14 - 65.18 
M 8 18.34 203.08 8.55 213.07 Q 8 8.01 118.85 - 59.53 
M 12 8.69 146.31 0 128.78 Q 12 3.4 86.52 0 52.72 
M 24 0 92.21 0 101.76 Q 24 0 49.69 0 33.56 
M 48 57.46 83.13 Q 48 25.04 19.12 
M 72 33.21 55.35 Q 72 28.46 15.08 
M 96 23.66 36.48 Q 96 23.48 13.2 
M 120 23.19 29.86 Q 120 17.36 8.58 
M 168 19.1 14.33 Q 168 15.78 5.84 
M 240 10.76 11.61 Q 240 22.52 4.85 
M 336 7.81 9.74 Q 336 15.72 -
M 480 - 4.36 Q 480 10.38 -
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I Appendix 0-3: Artesunate, OHAS, amodiaquine and O-amodiaquine individual PK graphs. 
Artesunate profiles 
Subject A: Artesunate 
100-,-------- - - - - --- ----, 
Qj' 75 
-1'0_ 
c: E ~ ~ 50 
~ 25 J~ 
o ll t.·--\., .. 
0.0 2.5 5.0 7.5 10.0 
Time (h) 
Subject C 
12.5 15.0 
300-,---------- - _ _ -, 
Qj' 
- 200 ~-~ E 
(/)~ ~ 
~ 
10: L 
0.0 2.5 5.0 7.5 10.0 
Time (h) 
12.5 15.0 
---Art alone 
- -. - Arno + Art 
--- Art alone 
-~ .... Arno + Art 
Subject B 
150~-----~--------, 
Qj' 
- 100 1'0_ 
c: E 
;jl-a, 
~c: 
~ 50 
"-, 
.
KA . 
o ". 
0.0 2.5 5.0 7.5 10.0 
Time (h) 
Subject 0 
12.5 15.0 
400~--------------, 
. 
Q) 300 h 
_ j l 
:! - , i ~ E i \ ~ -a, 200 ! ' 
t:: c: ! 
~ 1 \ 
100 \ 
l\\. i ' • .. ___ .,. o "-
00 2.5 5.0 7.5 10.0 
Time (h) 
12.5 15.0 
--Art alone 
' - 1 -- Arno + Art 
--- Art alone 
- .- Arno + Art 
Subject E 
300.-------------------------~ 
'Qj' 
- 200 §E 
i ~ 100 
2.5 5.0 7.5 10.0 12.5 15.0 
Time (h) 
SubjectJ 
100.-------------------------~ 
5.0 7.5 10.0 12 .5 15.0 
Time (h) 
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- Art alone 
······- Amo + Art 
- Art alone 
_ ..•.... Arne + Art 
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Subject F 
300~------------------------~ 
'Qj' 
- 200 §E 
~~ 
~ 100 
'Qj' 
-
o ~. ---
0.0 25 5.0 7.5 10.0 12.5 15.0 
Time (h) 
Subject K 
500.--------------------------
400 
§ E 300 
~~ ~ 200 
100 \\ 
~~" O~ ~~~--~~--._~~---
0.0 2.5 5.0 7.5 10.0 12 .5 15.0 
Time (h) 
- Art alone 
Amo + Art 
- Art alone 
~Amo+Art 
Subject L 
750,---------------------------. 
Qj' 
... 500 ~E _t::~ ~ 
c( 250 
Time (h) 
Subject P 
300~--------------------------~ 
Qj' 
... 200 nI_ 
C E ~~ ~ 100 \ ! ~ 
\ 
: ~ 
o 1 \~ 
0.0 2.5 
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5.0 7.5 10.0 12.5 15.0 
Time (h) 
- Art alone 
_ .---Amo + Art 
- Art alone 
.-- --.. Amo + Art 
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Subject M 
400~------------------------~ 
Q) 300 
... 
~-
:::l E ~ ~ 200 
~ 
100 
2.5 5.0 7.5 10.0 12.5 15.0 
Time (h) 
SubjectQ 
200,--------------------------, 
Qj' 
... 
~-
:::l E ~ ~ 100 
~ 
2.5 5.0 7.5 10.0 
Time (h) 
12.5 15.0 
--- Art alone 
.-0- Amo + Art 
- Art alone 
--~- Amo + Art 
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Subject N 
500-,-------------------, 
400 
'G;' 
.. 
~ E 300 
II! ~ 200 
...... 
100 
2.5 5.0 7.5 10.0 12.5 15.0 
Time (h) 
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-Art alone 
--Amo+Art 
Mean Artesunate Plot 
250.-----------------------------------~ 
2.5 
--Art alone 
-.~. Arno + Art 
5.0 7.5 
Time (h) 
10.0 12.5 
Artesunate + Dlhydroartesunate 
Arte.unate administered alone 
15.0 
1000.-----------------------------------------. 
--Artesunate 
- '- Dihydroartesunate 
0.0 2.5 5.0 7.5 10.0 12.5 15.0 
Time (h) 
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Dihydroartemisinin profiles 
C' 
'2 
'iii 
'E _ 
~E ~g, 
... 
"C 
>. 
.c 
9. 
C' 
'2 
'iii 
'E _ 
Q) E t:-a, ~ c: 
... 
"C 
>. 
.c 
9. 
18 
Subject A: Dihydroartemisinin 
1500.-----------------, 
1250 
1000 
750 
500 
250 
2.5 5.0 7.5 10.0 12.5 15.0 
Time (h) 
Subject C: Dihydroartemisinin 
1500.---------------. 
1250 
1000 
750 
500 
250 
2.5 5.0 7.5 10.0 12.5 15.0 
Time (h) 
- Art alone 
~Amo + Art 
--Art alone 
· .. · Amo + Art 
C' 
:§ 
I/) 
'E _ 
Q) E t:-a, ~ c: 
... 
"C 
>. 
.c 
9. 
C' 
'2 
'iii 
'E _ 
Q) E t:-a, ~c: 
... 
"C 
>. 
..c: 
C 
'-' 
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Subject B: Dihydroartemisinin 
1500-,--- ------- ------, 
1250 
1000 
750 
500 
250 
2.5 5.0 7.5 10.0 12 .5 15.0 
Time (h) 
Subject 0: Dihydroartemisinin 
1500..,------- - -----------, 
1250 
1000 
750 
500 
250 
2.5 5.0 7.5 10.0 12.5 15.0 
Time (h) 
--Art alone 
· ....... ··Amo + Art 
----- Art alone 
.--.... Amo + Art 
1 
Subject E: Dihydroartemisinin 
1500-,------------------, 
c 
'c 1250 
VI 
'E _ 1000 
Q) E ~ C, 750 ~ c 
... 
'C 
>. 
..c 
e. 
500 
250 
2.5 5.0 7.5 10.0 12.5 15.0 
Time (h) 
Subject J: Dihydroartemisinin 
1500-,------------------, 
c 
'c 1250 
'iii 
'E _ 1000 
Q) E ~c, 750 ~ c 
... 
'C 500 >. 
..c 
e. 250 
2.5 5.0 7.5 10.0 12.5 15.0 
Time (h) 
- Art alone 
-.~- Amo + Art 
- Art alone 
.-~- Amo + Art 
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Subject F: Dihydroartemisinin 
1500-,----------------, 
'c 1250 
'iii 
'E _ 1000 
Q) E ~ g, 750 
... 
-g, 500 
..c 
e. 250 ......... 
.............. ,."" ... ~ ...•.. 
O~·~··-,-~~~~--_,---._-~ 
c 
'c 
'iii 
'E _ 
Q) E ~c, ~ c 
... 
'C 
>. 
..c 
e. 
0.0 2.5 5.0 7.5 10.0 12.5 15.0 
Time (h) 
Subject K: Dihydroartemisinin 
1500,--------------, 
1250 
1000 
750 
500 
250 i \ .. t~··\ . 
, ~ ....•. ---~ .-... -.... . ~-. - -~.---O+L-~~~~~~==~--~-~ 
0.0 2.5 5.0 7.5 10.0 
Time (h) 
12.5 15.0 
--Art alone 
-··- Amo + Art 
--Art alone 
··- ···· Amo + Art 
1 
Subject L: Dihydroartemisinin 
1500,---------------------, 
'C 
'c 1250 
'iii 
'E _ 1000 
Q) E 
t:: c, 750 ~ c 
... 
'C 
~ 
C 
...... 
500 
250 
2.5 5.0 7.5 10.0 12.5 15.0 
Time (h) 
Subject P: Dihydroartemisinin 
1500,---------------------, 
'C 
'c 
VI 
'E_ 
Q) E 
t::c, ~ c 
... 
'C 
>-
.c::: 
B. 
1250 
1000 
750 
500 
250 
2.5 5.0 7.5 10.0 12.5 15.0 
Time (h) 
- Art alone 
-..... - . Arno + Art 
- Art alone 
.~-- Arno + Art 
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Subject M: Dihydroartemisinin 
1500,-----------------, 
'c 1250 
'iii 
'E _ 1000 
~.§ 
~ g' 750 
... 
'C 
~ 
C 
...... 
'C 
'c 
'iii 
'E _ 
Q) E 
t::-~g' 
... 
'C 
>-
.c::: 
B. 
500 
250 
2.5 5.0 7.5 10.0 12.5 15.0 
Time (h) 
Subject Q: Dihydroartemisinin 
1500,-----------------, 
1250 
1000 
750 
500 
250 
O+L--,-~~==r_--,_-~-~ 
0.0 2.5 5.0 7.5 10.0 12.5 15.0 
Time (h) 
- Art alone 
.......... Arno + Art 
~Artalone 
_ .... - Arno + Art 
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Subject N: Dihydroartemisinin 
1500.------------------, 
'C 
'2 1250 
'iii 
'E _ 1000 
~E 2! ~ 750 
... 
~ 500 
B 250 
2.5 5.0 7.5 10.0 12 .5 15.0 
Time (h) 
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-Art alone 
.. ...,.···· Amo + Art 
Amodiaquine profiles 
18 May ~uuo 
Subject A: Amodiaquine 
50~------------------------~ 
\'" 
10 ! "'oc ••• ....... 
... _ ._-_ ...•. _._._---_._ .......... .. 
O~----~--~----~----~~~ 
o 5 10 15 20 25 
Time (h) 
Subject C: Amodiaquine 
50',---------------------------
10 
5 10 15 20 25 
Time (h) 
- Amoalone 
... - - . Amo + Art 
--Amo alone 
._ .- Amo + Art 
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Subject B: Amodiaquine 
50,--------------------------, 
25 
Time (h) 
Subject 0: Amodiaquine 
50,-------------------------~ 
. ..", .... .......... . 
..... 
.•. -.... -.--... --.-~ ... --.. 
o~----~--~~--~----~~~ 
o 5 10 15 20 25 
Time (h) 
--Amoalone 
-'~"- Amo + Art 
--Amo alone 
..... .... Amo + Art 
Subject E: Amodiaquine 
50,--------------------------, 
Q) 40 
c::: 
·s _ 
tT E 30 
.!!! C, 
~ c::: 20 
~ 
10 
5 10 15 20 25 
Time (h) 
Subject J: Amodiaquine 
50,--------------------------, 
Q) 40 
c::: 
·s _ 
tT E 30 
.!!! C, 
~ c::: 20 
~ 
10 
.~ 
......... 
o+-----,----,··~·· · ·~· --~----,_--~ 
o 5 10 15 20 25 
Time (h) 
-Arnoalone 
-" W- Arno + Art 
- Amoalone 
_·· .. ···- Arno + Art 
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Subject F: Amodiaquine 
50,_-------------------------, 
Q) 40 
c::: 
·s _ 
tT E 30 
.!!! C, 
~ c::: 20 
~ 
5 10 15 20 25 
Time (h) 
Subject K: Amodiaquine 
50,--------------------------, 
10 
5 10 15 20 25 
Time (h) 
- Arnoalone 
_ ........ Arno + Art 
- Arnoalone 
_ ..... _. Arno + Art 
Subject L: Amodiaquine 
50.-------------------------~ 
10 
O~----._--_.----_.----~==~ 
o 5 10 15 20 25 
Time (h) 
Subject P: Amodiaquine 
50.-------------------------~ 
Q) 40 
c 
'&.e 30 
,! c, 
~ c 20 
~ 
10 
..... ,. .............. . 
O~----~--~~--~----~--~ 
o 5 10 15 20 25 
Time (h) 
--Amo alone 
_ ...... - Amo + Art 
- Amoalone 
-.... .. ·- Amo + Art 
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Subject M: Amodiaquine 
50.--------------------------. 
10 i 
O~--~~--~~--,-----~~~ 
o 5 10 15 20 25 
Time (h) 
Subject Q: Amodiaquine 
50.--------------------------. 
10 
I-, 
., 
..... 
.•..  _ ............................. . 
O+---~--~~~==~=-~ 
o 5 10 15 20 25 
Time (h) 
--Amo alone 
-.- -- Amo + Art 
- Amoalone 
...... ···· Amo + Art 
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Mean Amodiquine Profile 
30~----------------------------~ 
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D-amodiaquine profiles 
18 
Subject A: D-Amodiaquine 
700,--------------------------, 
~ 600 
'3 500 
0"_ 
,!!! E 400 
~ ~ 300 
~ 200 
..... 
100 
100 200 300 400 500 
Time (h) 
Subject C: D-Amodiaquine 
W 
700,--------------------------, 
600 
'3 500 
0"_ 
,!!! E 400 
'80, 
E I: 300 
~ o 200 
..... 
100 ~ ". O'~' 
o 100 200 300 400 500 
Time (h) 
- Amoalone 
---.-- Amo + Art 
--Amo alone 
.. ~ .... Amo + Art 
Page 104 of 137 
Subject B: D-Amodiaquine 
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I Appendix E .. 1: HPLC methodology for AS and DHAS 
A high performance liquid chromatographic (HPLC) method for the determination of 
artesunate and dyhydroartemisinin in human plasma 
References: 
Batty, K.T. et al (1996) J. Chromatography 677345 - 350 
Navaratnam V. et al (1997) J. Chromatography 692157 - 162 
1. PURPOSE 
To describe a High Performance Liquid Chromatographic (HPLC) method for the 
determination of artesunate and dyhydroartemisinin in human plasma to be 
performed at the Department of Pharmacology, University of Cape Town. 
2. APPLICABILITY 
All projects in the HPLC laboratory dealing with artesunate and dyhydroartemisinin in 
human plasma. 
3. RESPONSIBILITY 
Applicable to the persons responsible for the performance of assays on artesunate 
and dyhydroartemisinin in human plasma. 
4. PROCEDURE 
4.1 Description of assay components 
Matrix 
Anticoagulant 
Volume required 
Extraction method 
Concentration range 
Detection mode 
Quantitation by 
Regression 
18 May 2005 
human plasma 
heparin 
500 ul 
solid phase 
20 - 1000 ng/ml 
Postcolumn decomposition UV 290 nm 
peak area 
linear 
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4.2 INSTRUMENTATION 
SPECIFICATIONS 
NAME MODEUBRAND COMPANY 
Solvent pump 600 Multisolvent Delivery Waters 
System 
Autosampler WISP 712 Waters 
Detector 484 Tunable Abs. Detector Waters 
System Controller 600E Waters 
Integrator Peaksimple 
Analytical Column Symmetry C8 5 um Waters 
15 cm x 0,46 cm 
Guard column Pelliguard LC 8 Supelco 
2,5 cm x 0,46 cm Packed in house 
Centrifugal Vaccuum RC 10.10 Jouan 
Concentrator 
Low temperature trap RCT90 Jouan 
Vaccl!um extractor Analytichem I nt. 
4.3 CHEMICALS 
NAME SPECIFICATIONS COMPANY 
CAT NUMBER 
Water Type 1 Rgt grade Millipore In house 
Acetic acid 99,8% Merck Art 63 
Acetonitrile 99,9% BDH 152516Q 
Trifluoroacetic acid 99% Merck 808260 
Potassium hydroxide 98% Merck 4873 
Phenyl extraction 1 mll70 mg packing Varianl Anateck 
12102025 
column 
18 May 2005 
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I Appendix E-2: HPLC methodology for AQ and des-ethyl AQ 
A High Performance Liquid Chromatographic (HPLC)-Mass Spectrometric Method for 
the Determination of amodiaquine and desethylamodiaquine in Human Plasma 
NB: All procedures must be carried out under yellow light conditions. All HPLC vials 
must be amber. 
1. PURPOSE 
To describe a High Performance Liquid Chromatographic (HPLC) method for 
the determination of amodiaquine and desethylamodiaquine in human plasma 
to be performed at the Division of Pharmacology, Department of Medicine, 
University of Cape Town. 
2. APPLICABILITY 
This procedure applies to all projects in the HPLC laboratory dealing with 
amodiaquine and desethylamodiaquine in human plasma. 
3. RESPONSIBILITY 
This procedure applies to all the persons responsible for performing assays 
for amodiaquine and desethylamodiaquine in human plasma. 
4. PROCEDURE 
4.1 Description of assay components 
Matrix human plasma (heparin added as an 
anticoagulant) 
Sample Volume required 
Extraction method 
Concentration range 
Detection mod 
Quantitation 
Regression 
18 May 2005 
50 J.l1 
protein precipitation 
amodiaquine: 5 -100 ng/ml 
Desethylamodiaquine: 5 - 400 ng/ml 
Mass Spectrometer 
Peak area 
linear 
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4.2 Instrumentation Specifications 
~~~~l:lft;}e.~J ,.' ... ==-=~~-~ 
HPLC Agilent Hewlet 
Packard 
Detector Mass Hewlet 
Spectrometer Packard 
Analytical Column Xterra C18 50 x Waters 
4.6mm 
Guard Column Pelliguard LC18 Supelco 
2.5 cm x 0.46 Packed in 
cm house 
18 May 2005 
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4.4 Chemical Specifications 
@Dl§lHW '~it'iffi~ ~ {CF.fF.1 mm:m 
-
.:~"". .. i.. ,,:,ii';ftl;7":"':;"'\".'l\.;,@!Iii~''O'":'''';:~'''J<.:\'i".' . , 
Water Type 1, Reagent Millipore In house 
Grade purification 
Methanol 99.8% 8DH 1015868 
Acetonitrile 99.9% 8DH 152516Q 
Ammonia 98.0 Merck 001116.500 
4.5 Preparation of Stock Solutions 
4.5.1 
4.5.2 Amodiaquine/Desamo: Standard Solution A (1 mg/ml) 
a. On an analytical balance weigh approximately 1 mg of amodiaquine or 
metabolite into a clean polypropylene microcentrifuge tube. 
b. Add acetonitrile to produce a final concentration of 1 mg/ml. Vortex well. 
c. Store at minus 80 degrees centigrade. 
Amodiaquinel Desamo stock: Standard Solution B (0,01 mg/ml) 
a. Accurately pipette 10 ul of Standard Solution A into a 
polypropylene tube. 
b. Add 990 ul acetonitrile 
c. Store at minus 80 degrees centigrade 
Mobile Phase preparation 
4.6.2 Mobile P.hase: 75% acetonitrile: pH 10.6 with ammonia 
4.7 Preparation of calibration standards in plasma 
a. Obtain 200 ml drug-free human plasma, which has been screened for 
interference at the appropriate retention times. Allow the plasma to thaw 
at room temperature. 
b. Pipette 25 mls of plasma into clean 25 ml volumetric flasks 
18 May 2005 
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I Appendix F: Hepatitis case report 
Orrell C, Taylor W, Olliaro P. (2001). Acute asymptomatic hepatitis in a healthy 
normal volunteer exposed to 2 oral doses of amodiaquine and artesunate. 
Trans R Soc Trop Med Hygiene. 95(5): 517MB. September 2002. 
Multidrug resistant Plasmodium falciparum is a global problem (Wernsdorfer & 
Payne, 1991). The use of antimalarial drug combinations with independent 
mechanisms of action is a rational approach to delay the onset the of drug resistance 
and safeguard existing drugs (White & Olliaro, 1996). Current field research is 
assessing oral artesunate combined with standard antimalarials e.g. 
sulfadoxine/pyrimethamine, amodiaquine, for treating acute uncomplicated 
falciparum malaria. Artesunate has a short half life and produces a rapid and 
substantial reduction of malaria parasites; those that remain are then killed by the 
combinant drug acting over a longer time period. To complement the field studies, an 
interactive pharmacokinetic study of artesunate and amodiaquine was conducted in 
normal human volunteers at the University of Cape Town. We report the occurrence 
of asymptomatic hepatitis in a woman during this study. 
This was a single dose three phase cross over study conducted in 15 volunteers, 10 
male and 5 female, of age range 19 to 42 years. All volunteers received one dose of 
oral artesunate (4mg/kg) on day 0, followed, on day 7, by either one dose of oral 
amodiaquine (10 mg/kg) alone or combined with a single dose of artesunate 
(4mg/kg). Subjects were given the alternate regimen on day 28. Blood for routine 
haematology and biochemistry was taken on days 0, 6, 27 and 48. 
Our subject was a healthy 20 years old, South African female of African - Caucasian 
descent, with no previous significant illnesses. During the study she did not take any 
prescribed or over the counter drugs, including paracetamol, and had no reported 
drug allergies. She did not drink alcohol and had no risk factors for hepatitis B. Her 
family history was unremarkable. Clinically, there were no abnormal physical signs 
and her baseline blood tests were all normal. She received artesunate (day 0), 
amodiaquine (day 7), followed by the combination (day 28). Six days after taking 
artesunate alone, her AST and total bilirubin were normal but she had a slight 
increase in ALT of 31 lUlL (normal 1-25 lUlL) that was not considered clinically 
significant (figure 1). On day 27, all blood tests were normal. On day 48, her 
18 May 2005 
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I Appendix G-1: Haematology mean values 
SUMMARY OF HAEMATOLOGY MEASUREMENTS - TREATMENT MEANS AND CONFIDENCE 
INTERVALS 
Haemoglobin (g/dL) 
Treatment I Mean Std. Err. [95% Conf. IntervalJ 
------------------+---------------------------------------------------------
Baseline 14.0538 .4074 [13.1662 14.9415J 
Sodium Artesunate 13.7769 .3732 [12.9639 14.5900J 
Combination 13.9000 .3686 [13.0968 14.7032J 
Arnadiaquine 14.2154 .3993 [13.3453 15.0855J 
Haematocrit 
Treatment Mean Std. Err. [95% Conf. Interval] 
------------------+---------------------------------------------------------
Baseline .4331 .0117 [.4075 .45861 
Sodium Artesunate .4234 .0107 [.4006 .4471J 
Combination .4123.0109 [.3886.4360] 
Arnadiaquine .4223 .0098 [.4011 .4436J 
Platelet count (x10- 9 /L) 
Treatment Mean Std. Err. [95% Conf. Interval] 
------------------+---------------------------------------------------------
Baseline 235.1538 11.6789 [209.7078 260.5999] 
Sodium Artesunate 223.3077 9.9049 [201.7267 244.8887] 
Combination 244.5385 11.3203 [219.8737 269.2032J 
Arnadiaquine 230.6154 11.4922 [205.576 255.6548J 
White cell count (xlO-9/L) 
Treatment Mean Std. Err. [95% Conf. Interval] 
------------------+---------------------------------------------------------
Baseline 7.0923 .4779 [6.0510 8.1336] 
Sodium Artesunate 6.1538 .4174 [5.2445 7.0632] 
Combination 5.6923 .4736 [4.6604 6.7242J 
Arnadiaquine 5.3923 .3259 [4.6822 6.1024] 
Neutrophils (x10- 9 /L) 
Treatment Mean Std. Err. [95% Conf. Interva11 
------------------+---------------------------------------------------------
Baseline 3.7869 .4140 [2.8848 4.6890] 
Sodium Artesunate 3.1785 .2813 [2.5656 3.7913] 
Combination 3.0923 .2888 [2.4630 3.7217] 
Arnadiaquine 2.8100 .2123 [2.3475 3.2725] 
Lymphocytes (x10- 9 /L) 
Treatment Mean Std. Err. [95% Conf. Interval] 
------------------+---------------------------------------------------------
Baseline 2.5254 .2087 [2.0706 2.9802] 
Sodium Artesunate 2.2246 .2162 [1.7535 2.6958] 
Combination 1.9908 .1829 [1.5922 2.3894] 
Arnadiaquine 1.9846 .1321 [1.6968 2.2724] 
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[] Mean 
I ±0.95 Conf. Interval 
[] Mean 
I ±0.95 Conf. Interval 
Demographic variables: 
Subject 
A 
B 
C 
0 
E 
F 
G 
H 
J 
K 
L 
M 
N 
P 
Q 
Mean: 
Std deviation: 
18 May 2005 
race 
c 
c 
w 
w 
b 
w 
w 
b 
a 
b 
c 
c 
a 
w 
b 
b=black 
c=coloured 
w=white 
age 
(years) 
20 
42 
23 
22 
23 
34 
23 
22 
19 
24 
22 
21 
23 
24 
24 
24.4 
5.90 
gender 
f 
m, 
m 
m, 
f 
rn 
m 
f 
f 
f 
m 
m 
m 
m 
m 
f=female 
m=male 
weight 
(kg) 
69 
70 
82 
63 
68 
73 
61 
59 
50 
54 
74 
97 
68 
64 
58 
67.33 
11.61 
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height 
(cm) 
169 
166 
185 
173 
158 
180 
171 
159 
161 
157 
181 
189 
176 
179 
159 
170.87 
10.61 
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1 Appendix G-2: Change in haematological parameters 
Haemoglobin (g/dL) 
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I Appendix G-3: Individual haematological parameters. ] 
White cell count (x10e9/L) 
Subject Code AS in phase 2 or 3 Sex baseline day 6 safety day 27 safety day 48 safety 
phase 1 - AS only phase 2 - AQ +/- AS phase 3 - AQ +/- AS 
BL-01 Q 3 m 9.6 7.8 7.4 9.3 
TM-02 F 2 m 4.9 5.3 5.8 4.8 
BT-03 L 2 m 6.5 7.5 5.4 7.0 
TKM-07 K 2 f 5.2 5.2 3.2 4.3 
TIM-08 E 3 f 5.7 4.2 3.2 3.4 
CB-09 P 3 m 10.6 7.3 5.8 5.8 
GL-11 0 2 m 5.2 5.6 4.7 5.7 
NS-12 B 2 m 6.3 4.6 5.5 5.6 
SB-14 N 2 m 7.7 6.3 6.2 6.1 
OS-15 C 3 m 7.8 4.6 4.3 5.5 
AAS-16 J 3 f 7.3 9.4 6.3 8.6 
MA-17 M 3 m 8.2 6.4 4.6 4.9 
AS-18 A 3 f 7.2 5.8 5.0 5.7 
MEAN 7.09 6.15 5.18 5.90 
Withdrawn: 
SV-10 G 3 m 5.6 5.5 5.4 ~ithdrew day 7- allergic reaction to AQ 
CL19 H 2 f 9.1 6.5 4.3 ithdrew at day 28 - began fluoxetine 
Screen failures: 
RM-04 m 2.9 screen failure - neutropaenia 
MM-05 f 5.2 screen failure - chose not to commence 
US-06 f 5.9 screen failure - chose not to commence 
RW-13 m 3.4 screen failure - neutropaenia 
18 May 2005 
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Neutrophils (x10e9/L) 
Subject Code AS in phase 2 or 3 Sex baseline day 6 safety day 27 safety day 48 safety 
phase 1 - AS only phase 2 - AO +/- AS phase 3 - AO +/- AS 
BL-01 0 3 m 7.3 4.87 4.17 4.88 
TM-02 F 2 m 2.31 2.65 3.85 2.53 
BT-03 L 2 m 3.72 4.54 3.05 3.9 
TKM-07 K 2 f 2.33 2.51 1.37 1.8 
TTM-08 E 3 f 2.33 2.01 1.7 1.89 
CB-09 P 3 m 6.35 4.69 2.97 3.19 
GL-11 0 2 m 3.37 2.98 2.68 3.56 
NS-12 B 2 m 3.21 2.15 .- 2.84 2.82 
SB-14 N 2 m 4.07 2.8 3.05 3.05 
OS-15 C 3 m 4.03 2.31 2.14 2.85 
AAS-16 J 3 f 3.44 4.05 2.82 4.84 
MA-17 M 3 m 2.99 2.48 2.08 2.03 
AS-18 A 3 f 3.78 3.28 2.99 3.68 hepatitis day 42 
MEAN 3.79 3.18 2.75 3.16 
Withdrawn: 
SV-10 G 3 ~I 3.07 2.61 2.62 ~ithdrew day 7- allergic reaction to AO CL 19 H 2 5.15 3.12 3.35 withdrew at day 28 - began fluoxetine 
Screen failures: 
RM-04 m 1.26 screen failure - neutropaenia 
MM-05 f 2.83 screen failure - chose not to commence 
US-06 f 3.56 screen failure - chose not to commence 
RW-13 m 1.53 screen failure - neutropaenia 
18 May 2005 
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Lymphocytes (x10e9/L) 
Subject Code AS in phase 2 or 3 Sex baseline day 6 safety day 27 safety day 48 safety 
phase 1 - AS only phase 2 - AQ +/- AS phase 3 - AQ +/- AS 
BL-01 Q 3 m 1.50 2.06 2.37 3.48 
TM-02 F 2 m 1.91 1.96 1.48 1.65 
BT-03 l 2 m 2.08 2.22 1.75 2.40 
TKM-07 K 2 f 2.26 2.04 1.50 2.02 
TTM-08 E 3 f 2.70 1.53 1.14 1.10 
CB-09 P 3 m 3.04 1.89 2.14 1.87 
GL-11 0 2 m 1.36 1.84 1.53 1.65 
NS-12 B 2 m 2.50 1.82 2.05 2.26 
SB-14 N 2 m 2.79 2.69 2.50 2.34 
OS-15 C 3 m 2.78 1.63 1.55 1.95 
AAS-16 J 3 f 3.16 4.32 2.78 2.81 
MA-17 M 3 m 4.23 3.23 2.14 2.42 
AS-18 A 3 f 2.52 1.69 1.36 1.44 hepatitis day 4. 
MEAN 2.53 2.22 1.87 2.11 
Withdrawn: 
SV-1Q G 3 m 1.82 2.16 2.19 ~ithdrew day 7- allergic reaction to AQ 
Cl19 H 2 f 3.03 2.63 2.88 ithdrew at day 28 - began fluoxetine 
Screen failures: 
RM-04 m 1.32 rreen failure - neutropaenia 
MM-05 f 1.88 screen failure - chose not to commence 
US-06 f 1.74 screen failure - chose not to commence 
RW-13 m 1.34 screen failure - neutropaenia 
18 May 2005 
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Haemoglobin (g/dL) 
Subject Code AS in phase 2 or 3 Sex Initial Hb day 6 safety day 27 safety day 48 safety 
phase 1 - AS only phase 2 - AQ +/- AS phase 3 - AQ +/- AS 
BL-01 Q 3 m 14.2 14.9 15.5 15.9 
TM-02 F 2 m 15.4 15.2 14.5 15.6 
BT-03 L 2 m 15.5 14.4 14.6 15.7 
TKM-07 K 2 f 11.4 11.9 12.0 12.5 
TTM-08 E 3 f 13.6 13.0 12.7 13.2 
CB-09 p 3 m 15.0 14.2 15.0 14.4 
GL-11 0 2 m 16.0 15.9 14.7 14.8 
NS-12 B 2 m 14.8 14.5 15.0 15.9 
SB-14 N 2 m 11.7 13.6 13.3 13.8 
OS-15 C 3 m 14.1 13.6 14.1 14.4 
AAS-16 J 3 f 12.5 11.6 11.7 11.2 
MA-17 M 3 m 15.1 14.4 15.0 14.8 
AS-18 A 3 f 13.4 11.9 12.5 12.7 hepatitis day 4. 
MEAN 14.05 13.78 13.89 14.22 
Withdrawn: 
SV-10 G 3 m 14.0 14.1 14.1 ~ithdrew day 7- allergic reaction to AQ 
CL19 H 2 f 11.3 10.7 10.4 withdrew at day 28 - began fluoxetine 
Screen failures: 
RM-04 m 14.7 screen failure - neutropaenia 
MM-05 f 13.6 screen failure - chose not to commence 
US-06 f 11.8 screen failure - chose not to commence 
RW-13 m 13.4 screen failure - neutropaenia 
18 May 2005 
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Haematocrit 
Subject Code AS in phase 2 or 3 Sex baseline day 6 safety day 27 safety day 48 safety 
phase 1 - AS only phase 2 - AQ +/- AS phase 3 - AQ +/- AS 
BL-01 Q 3 m 0.43 0.46 0.47 0.47 
TM-02 F 2 m 0.49 0.47 0.45 0.45 
BT-03 L 2 m 0.49 0.43 0.43 0.45 
TKM-07 K 2 f 0.35 0.37 0.37 0.36 
TIM-08 E 3 f 0.43 0.41 0.39 0.38 
CB-09 P 3 m 0.43 0.43 0.44 0.44 
GL-11 0 2 m 0.49 0.49 0.44 0.43 
NS-12 B 2 m 0.43 0.41 0.42 0.44 
SB-14 N 2 m 0.39 0.43 0.41 0.43 
OS-15 C 3 m 0.44 0.42 0.43 0.42 
AAS-16 J 3 f 0.4 0.37 0.37 0.33 
MA-17 M 3 m 0.46 0.45 0.45 0.43 
AS-18 A 3 f 0.4 0.37 0.38 0.37 hepatitis day 4. 
MEAN 0.43 0.42 0.42 0.42 
Withdrawn: 
SV-10 G 3 m 0.44 0.44 0.43 IWithdrew day 7- allergic reaction to AQ 
CL19 H 2 f 0.37 0.36 0.34 withdrew at day 28 - began f1uoxetine 
Screen failures: 
RM-04 m 0.45 screen failure - neutropaenia 
MM-05 f 0.45 screen failure - chose not to commence 
US-06 f 0.38 screen failure - chose not to commence 
RW-13 m 0.42 screen failure - neutropaenia 
18 May 2005 
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Platelet count (x10e9/L) 
Subject Code AS in phase 2 or 3 ,Sex baseline day 6 safety day 27 safety day 48 safety 
phase 1 - AS only phase 2 - AQ +/- AS phase 3 - AQ +/- AS 
BL-01 Q 3 m 240 203 226 266 
TM-02 F 2 m 221 207 308 209 
BT-03 L 2 m 254 241 237 257 
TKM-07 K 2 f 273 291 297 338 
TIM-08 E 3 f 197 229 193 238 
CB-09 P 3 m 323 277 275 295 
GL-11 D 2 m 185 194 192 220 
NS-12 B 2 m 206 198 190 218 
S8-14 N 2 m 200 200 200 220 
DS-15 C 3 m 193 194 186 233 
AAS-16 J 3 f 292 274 252 279 
MA-17 M 3 m 252 200 206 227 
AS-18 A 3 f 221 195 198 217 hepatitis day 4. 
MEAN 235.15 223.31 227.69 247A6 
Withdrawn: 
SV-10 G 3 m 210 231 224 IWithdrew day 7- allergic reaction to AQ 
CL19 H 2 f 295 288 withdrew at day 28 - began fluoxetine 
Screen failures: 
RM-04 m 184 screen failure - neutropaenia 
MM-05 f 279 screen failure - chose not to commence 
US-06 f 275 screen failure - chose not to commence 
RW-13 m 203 screen failure - neutropaenia 
18 May 2005 
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I Appendix H J 
Dosing variables: 
Subject weight Calculated AQ dose AQ dose given Actual AQ mg/kg Calculated AS dose AS dose given Actual AS mg/kg 
(kg) (10mgJ~gl (mg) (4mg/kg) (mg) 
A 69 690 800 11.59 46 300 4.35 
B 70 700 800 11.43 46 300 4.29 
C 82 820 800 9.76 39 350 4.27 
D 63 630 600 9.52 38 300 4.76 
E 68 680 800 11.76 47 300 4.41 
F 73 730 800 10.96 44 300 4.11 
G 61 610 600 - 9.84 39 250 4.10 
H 59 590 600 10.17 41 250 4.24 
J 50 500 600 12.00 48 200 4.00 
K 54 540 600 11.11 44 250 4.63 
L 74 740 800 10.81 43 300 4.05 
·M 97 970 1000 10.31 41 400 4.12 
N 68 680 800 11.76 47 300 4.41 
P 64 640 600 9.38 38 250 3.91 
Q 58 -580 600 10.34 41 250 4.31 
Mean: 67.33 10.72 4.26 . 
Std deviation: 11.61 0.88 0.23 
18 May 2005 
Demographic variables: 
Subject 
A 
B 
C 
0 
E 
F 
G 
H 
J 
K 
L 
M 
N 
P 
a 
Mean: 
Std deviation: 
18 May 2005 
race 
c 
c 
w 
w 
b 
w 
w 
b 
a 
b 
c 
c 
a 
W 
b 
b=black 
c=coloured 
w=white 
age 
{years} 
20 
42 
23 
22 
23 
34 
23 
22 
19 
24 
22 
21 
23 
24 
24 
24.4 
5.90 
gender 
f 
m, 
rn 
m 
f 
m, 
m 
f 
f 
f 
m 
m 
m 
m 
m 
f=female 
m=male 
weight 
(kg) 
69 
70 
82 
63 
68 
73 
61 
59 
50 
54 
74 
97 
68 
64 
58 
67,33 
11.61 
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height 
(cm) 
169 
166 
185 
173 
158 
180 
171 
159 
161 
157 
181 
189 
176 
179 
159 
170.87 
10.61 
